<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="http://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 http://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="47737293-0fc6-46fe-ba5e-214f12292433"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use ZEPATIER safely and effectively. See full prescribing information for ZEPATIER.<br/>
      <br/> ZEPATIERâ„¢ (elbasvir and grazoprevir) tablets, for oral use <br/>Initial U.S. Approval: 2016</title>
   <effectiveTime value="20160128"/>
   <setId root="164dc02a-9180-426a-b8b5-04ab39d2bbd4"/>
   <versionNumber value="2"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="001317601" root="1.3.6.1.4.1.519.1"/>
            <name>Merck Sharp &amp; Dohme Corp.</name>
            <assignedEntity>
               <assignedOrganization/>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section ID="DLDE">
               <id root="1a6f0259-b7be-4e76-8afa-6efb94dc3c9c"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PRODUCT DATA ELEMENTS SECTION"/>
               <effectiveTime value="20160128"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0006-3074" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>ZEPATIER</name>
                        <formCode code="C42931" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, FILM COATED"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>elbasvir and grazoprevir</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="50" unit="mg"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="632L571YDK" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ELBASVIR</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="632L571YDK" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>ELBASVIR</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="100" unit="mg"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="4O2AB118LA" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GRAZOPREVIR</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="4O2AB118LA" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>GRAZOPREVIR</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="D9C330MD8B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>COPOVIDONE K25-31</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="M28OL1HH48" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CROSCARMELLOSE SODIUM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="0VUT3PMY82" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE 2910 (3 MPA.S)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3OWL53L36A" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MANNITOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CELLULOSE, MICROCRYSTALLINE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM CHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="368GB5141J" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM LAURYL SULFATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="O03S90U1F2" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TOCOPHERSOLAN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="R12CBM0EIZ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CARNAUBA WAX</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="XM0M87F357" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERROSOFERRIC OXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="36SFW2JZ0W" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE 2910 (15 MPA.S)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="1K09F3G675" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERRIC OXIDE RED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EX438O2MRT" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERRIC OXIDE YELLOW</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="XHX3C3X673" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TRIACETIN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="14" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0006-3074-01" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43192" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="DOSE PACK"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="2" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0006-3074-02" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA208261" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20160128"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48332" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BROWN" xsi:type="CE">
                              <originalText>Beige</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48345" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OVAL" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="21" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">770</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="S1">
               <id root="1f776d6a-46a4-4749-a1c3-70fb1a1b98b4"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>ZEPATIERâ„¢ is indicated with or without ribavirin for the treatment of chronic hepatitis C virus (HCV) genotypes 1 or 4 infection in adults.</paragraph>
               </text>
               <effectiveTime value="20160128"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>ZEPATIER is a fixed-dose combination product containing elbasvir, a hepatitis C virus (HCV) NS5A inhibitor, and grazoprevir, an HCV NS3/4A protease inhibitor, and is indicated with or without ribavirin for treatment of chronic HCV genotypes 1 or 4 infection in adults. (<linkHtml href="#S1">1</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S2">
               <id root="ba7f2818-1f98-4698-a411-4aac573bc16f"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20160128"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>Testing prior to initiation: 									<list listType="unordered" styleCode="disc">
                                 <item>Genotype 1a: Testing for the presence of virus with NS5A resistance-associated polymorphisms is recommended. (<linkHtml href="#S2.1">2.1</linkHtml>)</item>
                                 <item>Obtain hepatic laboratory testing. (<linkHtml href="#S2.1">2.1</linkHtml>)</item>
                              </list>
                           </item>
                           <item>Recommended dosage: One tablet taken orally once daily with or without food. (<linkHtml href="#S2.2">2.2</linkHtml>)</item>
                        </list>
                        <table width="100%">
                           <caption>Dosage Regimens and Durations for ZEPATIER in Patients with Genotype 1 or 4 HCV with or without Cirrhosis</caption>
                           <col width="50%" align="center" valign="top"/>
                           <col width="25%" align="center" valign="bottom"/>
                           <col width="25%" align="center" valign="bottom"/>
                           <thead>
                              <tr>
                                 <th styleCode="Lrule Rrule" valign="bottom">Patient Population</th>
                                 <th styleCode="Rrule">Treatment</th>
                                 <th styleCode="Rrule">Duration</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Genotype 1a: <br/>Treatment-naÃ¯ve or PegIFN/RBV-experienced<footnote ID="foot1">Peginterferon alfa + ribavirin.</footnote>Â <content styleCode="underline">without</content> baseline NS5A polymorphisms<footnote ID="foot2">Polymorphisms at amino acid positions 28, 30, 31, or 93.</footnote>
                                 </td>
                                 <td styleCode="Rrule">ZEPATIER</td>
                                 <td styleCode="Rrule">12 weeks</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Genotype 1a: <br/>Treatment-naÃ¯ve or PegIFN/RBV-experienced<footnoteRef IDREF="foot1"/>Â <content styleCode="underline">with</content> baseline NS5A polymorphisms<footnoteRef IDREF="foot2"/>
                                 </td>
                                 <td styleCode="Rrule">ZEPATIER + ribavirin</td>
                                 <td styleCode="Rrule">16 weeks</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Genotype 1b: <br/>Treatment-naÃ¯ve or PegIFN/RBV-experienced<footnoteRef IDREF="foot1"/>
                                 </td>
                                 <td styleCode="Rrule">ZEPATIER</td>
                                 <td styleCode="Rrule">12 weeks</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Genotype 1a or 1b: PegIFN/RBV/PI-experienced<footnote>Peginterferon alfa + ribavirin + HCV NS3/4A protease inhibitor.</footnote>
                                 </td>
                                 <td styleCode="Rrule" valign="top">ZEPATIER + ribavirin</td>
                                 <td styleCode="Rrule">12 weeks</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Genotype 4: <br/>Treatment-naÃ¯ve</td>
                                 <td styleCode="Rrule">ZEPATIER</td>
                                 <td styleCode="Rrule">12 weeks</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">Genotype 4: <br/>PegIFN/RBV-experienced<footnoteRef IDREF="foot1"/>
                                 </td>
                                 <td styleCode="Rrule" valign="top">ZEPATIER + ribavirin</td>
                                 <td styleCode="Rrule">16 weeks</td>
                              </tr>
                           </tbody>
                        </table>
                        <list listType="unordered">
                           <item>HCV/HIV-1 co-infection: Follow the dosage recommendations in the table above. (<linkHtml href="#S2.2">2.2</linkHtml>)</item>
                           <item>Renal Impairment, including hemodialysis: No dosage adjustment of ZEPATIER is recommended. Refer to ribavirin prescribing information for ribavirin dosing and dosage modifications. (<linkHtml href="#S2.3">2.3</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S2.1">
                     <id root="53cb763a-d101-4bb6-9964-5286d8ee2f60"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1	Testing Prior to the Initiation of Therapy </title>
                     <effectiveTime value="20160128"/>
                     <component>
                        <section>
                           <id root="5a28081d-2ad3-43c6-8118-79fcd981bb2b"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">NS5A Resistance Testing in HCV Genotype 1a-Infected Patients</content>
                              </paragraph>
                              <paragraph>Testing patients with HCV genotype 1a infection for the presence of virus with NS5A resistance-associated polymorphisms is recommended prior to initiation of treatment with ZEPATIER to determine dosage regimen and duration <content styleCode="italics">[see <linkHtml href="#S2.2">Dosage and Administration (2.2)</linkHtml>], <linkHtml href="#t1">Table 1</linkHtml>
                                 </content>. In subjects receiving ZEPATIER for 12 weeks, sustained virologic response (SVR12) rates were lower in genotype 1a-infected patients with one or more baseline NS5A resistance-associated polymorphisms at amino acid positions 28, 30, 31, or 93 <content styleCode="italics">[see <linkHtml href="#S12.4">Microbiology (12.4)</linkHtml>], <linkHtml href="#t11">Table 11</linkHtml>
                                 </content>. </paragraph>
                           </text>
                           <effectiveTime value="20160128"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="d64f4763-9a19-47af-926e-3a5af305eae0"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Hepatic Laboratory Testing</content>
                              </paragraph>
                              <paragraph>Obtain hepatic laboratory testing prior to and during treatment with ZEPATIER <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>].</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20160128"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S2.2">
                     <id root="282635f4-7ab2-4b03-90c4-3e8fc62ddd2f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2	Recommended Dosage in Adults</title>
                     <text>
                        <paragraph>ZEPATIER is a two-drug, fixed-dose combination product containing 50 mg of elbasvir and 100 mg of grazoprevir in a single tablet. The recommended dosage of ZEPATIER is one tablet taken orally once daily with or without food <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>. ZEPATIER is used in combination with ribavirin in certain patient populations (see <linkHtml href="#t1">Table 1</linkHtml>). When administered with ZEPATIER, the recommended dosage of ribavirin in patients without renal impairment is weight-based administered in two divided doses with food. For further information on ribavirin dosing and dosage modifications, refer to the ribavirin prescribing information.</paragraph>
                     </text>
                     <effectiveTime value="20160128"/>
                     <component>
                        <section>
                           <id root="0498144c-656c-48c3-9475-d87c3405ca12"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Treatment Regimen and Duration of Therapy</content>
                              </paragraph>
                              <paragraph>Relapse rates are affected by baseline host and viral factors and differ between treatment regimens and durations for certain subgroups <content styleCode="italics">[see <linkHtml href="#S14">Clinical Studies (14)</linkHtml>].</content>
                              </paragraph>
                              <paragraph>
                                 <linkHtml href="#t1">Table 1</linkHtml> below provides the recommended ZEPATIER treatment regimen and duration based on the patient population and genotype in HCV mono-infected and HCV/HIV-1 co-infected patients with or without cirrhosis and with or without renal impairment including patients receiving hemodialysis. </paragraph>
                              <table width="90%" ID="t1">
                                 <caption>Table 1: Recommended Dosage Regimens and Durations for ZEPATIER for Treatment of HCV Genotype 1 or 4 in Patients with or without Cirrhosis</caption>
                                 <col width="50%" align="left" valign="top"/>
                                 <col width="25%" align="center" valign="top"/>
                                 <col width="25%" align="center" valign="top"/>
                                 <thead>
                                    <tr>
                                       <th styleCode="Lrule Rrule" valign="bottom" align="center">Patient Population</th>
                                       <th styleCode="Rrule" valign="bottom">Treatment</th>
                                       <th styleCode="Rrule" valign="bottom">Duration</th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Genotype 1a: Treatment-naÃ¯ve or PegIFN/RBV-experienced<footnote ID="t1f1">Patients who have failed treatment with peginterferon alfa (PegIFN) + ribavirin (RBV).</footnote>Â <content styleCode="underline">without</content> baseline NS5A polymorphisms<footnote ID="t1f2">NS5A resistance-associated polymorphisms at amino acid positions 28, 30, 31, or 93. See <linkHtml href="#S2.1">section 2.1</linkHtml> Testing prior to the initiation of therapy, subsection NS5A resistance testing in HCV genotype 1a-infected patients.</footnote>
                                       </td>
                                       <td styleCode="Rrule">ZEPATIER</td>
                                       <td styleCode="Rrule">12 weeks</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Genotype 1a: Treatment-naÃ¯ve or PegIFN/RBV-experienced<footnoteRef IDREF="t1f1"/>Â <content styleCode="underline">with</content> baseline NS5A polymorphisms<footnoteRef IDREF="t1f2"/>
                                       </td>
                                       <td styleCode="Rrule">ZEPATIER + RBV<footnote ID="t1f3">For patients with CrCl greater than 50 mL per minute, the recommended dosage of ribavirin is weight-based (less than 66 kg = 800 mg per day, 66 to 80 kg = 1000 mg per day, 81 to 105 kg = 1200 mg per day, greater than 105 kg = 1400 mg per day) administered in two divided doses with food. For patients with CrCl less than or equal to 50 mL per minute, including patients receiving hemodialysis, refer to the ribavirin tablet prescribing information for the correct ribavirin dosage.</footnote>
                                       </td>
                                       <td styleCode="Rrule">16 weeks</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Genotype 1b: Treatment-naÃ¯ve or PegIFN/RBV-experienced<footnoteRef IDREF="t1f1"/>
                                       </td>
                                       <td styleCode="Rrule">ZEPATIER</td>
                                       <td styleCode="Rrule">12 weeks</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Genotype 1a<footnote>The optimal ZEPATIER-based treatment regimen and duration of therapy for PegIFN/RBV/PI-experienced genotype 1a-infected patients with one or more baseline NS5A resistance-associated polymorphisms at positions 28, 30, 31, and 93 has not been established.</footnote> or 1b: PegIFN/RBV/PI-experienced<footnote>Patients who have failed treatment with PegIFN + RBV + HCV NS3/4A protease inhibitor (PI): boceprevir, simeprevir, or telaprevir.</footnote>
                                       </td>
                                       <td styleCode="Rrule">ZEPATIER + RBV<footnoteRef IDREF="t1f3"/>
                                       </td>
                                       <td styleCode="Rrule">12 weeks</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Genotype 4: Treatment-NaÃ¯ve</td>
                                       <td styleCode="Rrule">ZEPATIER</td>
                                       <td styleCode="Rrule">12 weeks</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Genotype 4: PegIFN/RBV-experienced<footnoteRef IDREF="t1f1"/>
                                       </td>
                                       <td styleCode="Rrule">ZEPATIER + RBV<footnoteRef IDREF="t1f3"/>
                                       </td>
                                       <td styleCode="Rrule">16 weeks</td>
                                    </tr>
                                 </tbody>
                              </table>
                           </text>
                           <effectiveTime value="20160128"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S2.3">
                     <id root="fd458533-e4f4-48d9-86cc-48a6ac1cb38f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3	Renal Impairment </title>
                     <text>
                        <paragraph>No dosage adjustment of ZEPATIER is recommended in patients with any degree of renal impairment including patients on hemodialysis. Administer ZEPATIER with or without ribavirin according to the recommendations in <linkHtml href="#t1">Table 1</linkHtml>
                           <content styleCode="italics">[see <linkHtml href="#S8.8">Use in Specific Populations (8.8)</linkHtml> and <linkHtml href="#S14.4">Clinical Studies (14.4)</linkHtml>]</content>. Refer to the ribavirin tablet prescribing information for the correct ribavirin dosage for patients with CrCl less than or equal to 50 mL per minute. </paragraph>
                     </text>
                     <effectiveTime value="20160128"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.4">
                     <id root="ab82042c-c6d9-4664-8acb-ab3ec3e65d3b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.4	Hepatic Impairment </title>
                     <text>
                        <paragraph>No dosage adjustment of ZEPATIER is recommended in patients with mild hepatic impairment (Child-Pugh A). ZEPATIER is contraindicated in patients with moderate or severe hepatic impairment (Child-Pugh B or C) <content styleCode="italics">[see <linkHtml href="#S4">Contraindications (4)</linkHtml>, <linkHtml href="#S8.9">Use in Specific Populations (8.9)</linkHtml>, and <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20160128"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S3">
               <id root="83004d4d-9c7e-4fec-bb20-6cafe22e0ce4"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>ZEPATIER is available as a beige-colored, oval-shaped, film-coated tablet debossed with "770" on one side and plain on the other. Each tablet contains 50 mg elbasvir and 100 mg grazoprevir.</paragraph>
               </text>
               <effectiveTime value="20160128"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>Tablets: 50 mg elbasvir and 100 mg grazoprevir (<linkHtml href="#S3">3</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S4">
               <id root="e85347a7-51e0-4150-9c86-c590147c07bf"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <list listType="unordered">
                     <item>ZEPATIER is contraindicated in patients with moderate or severe hepatic impairment (Child-Pugh B or C) due to the expected significantly increased grazoprevir plasma concentration and the increased risk of alanine aminotransferase (ALT) elevations <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>, <linkHtml href="#S8.9">Use in Specific Populations (8.9)</linkHtml>, and <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>.</item>
                     <item>ZEPATIER is contraindicated with organic anion transporting polypeptides 1B1/3 (OATP1B1/3) inhibitors, strong inducers of cytochrome P450 3A (CYP3A), and efavirenz <content styleCode="italics">[see <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>, <linkHtml href="#S7">Drug Interactions (7)</linkHtml>, and <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>.</item>
                     <item>If ZEPATIER is administered with ribavirin, the contraindications to ribavirin also apply to this combination regimen. Refer to the ribavirin prescribing information for a list of contraindications for ribavirin.</item>
                  </list>
                  <paragraph>
                     <linkHtml href="#t2">Table 2</linkHtml> lists drugs that are contraindicated with ZEPATIER.</paragraph>
                  <table width="90%" ID="t2">
                     <caption>Table 2: Drugs that are Contraindicated with ZEPATIER</caption>
                     <col width="25%" align="left" valign="top"/>
                     <col width="30%" align="left" valign="top"/>
                     <col width="45%" align="left" valign="top"/>
                     <thead>
                        <tr>
                           <th styleCode="Rrule Lrule" align="center" valign="middle">Drug Class</th>
                           <th styleCode="Rrule">Drug(s) within Class that are Contraindicated</th>
                           <th styleCode="Rrule" align="center" valign="middle">Clinical Comment<footnote>This table is not a comprehensive list of all drugs that inhibit OATP1B1/3 or strongly induce CYP3A.</footnote>
                           </th>
                        </tr>
                     </thead>
                     <tbody>
                        <tr styleCode="Botrule">
                           <td styleCode="Rrule Lrule">Anticonvulsants</td>
                           <td styleCode="Rrule">Phenytoin<br/>Carbamazepine </td>
                           <td styleCode="Rrule">May lead to loss of virologic response to ZEPATIER due to significant decreases in elbasvir and grazoprevir plasma concentrations caused by strong CYP3A induction.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Rrule Lrule">Antimycobacterials</td>
                           <td styleCode="Rrule">Rifampin</td>
                           <td styleCode="Rrule">May lead to loss of virologic response to ZEPATIER due to significant decreases in elbasvir and grazoprevir plasma concentrations caused by strong CYP3A induction.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Rrule Lrule">Herbal Products</td>
                           <td styleCode="Rrule">St. John's Wort (Hypericum perforatum)</td>
                           <td styleCode="Rrule">May lead to loss of virologic response to ZEPATIER due to significant decreases in elbasvir and grazoprevir plasma concentrations caused by strong CYP3A induction.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Rrule Lrule">HIV Medications</td>
                           <td styleCode="Rrule">Efavirenz<footnote>Efavirenz is included as a strong CYP3A inducer in this table, since co-administration reduced grazoprevir exposure by â‰¥80% <content styleCode="italics">[see <linkHtml href="#t8">Table 8</linkHtml>]</content>.</footnote>
                           </td>
                           <td styleCode="Rrule">May lead to loss of virologic response to ZEPATIER due to significant decreases in elbasvir and grazoprevir plasma concentrations caused by CYP3A induction.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Rrule Lrule">HIV Medications</td>
                           <td styleCode="Rrule">Atazanavir<br/>Darunavir<br/>Lopinavir<br/>Saquinavir<br/>Tipranavir</td>
                           <td styleCode="Rrule">May increase the risk of ALT elevations due to a significant increase in grazoprevir plasma concentrations caused by OATP1B1/3 inhibition.</td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule">Immunosuppressants</td>
                           <td styleCode="Rrule">Cyclosporine</td>
                           <td styleCode="Rrule">May increase the risk of ALT elevations due to a significant increase in grazoprevir plasma concentrations caused by OATP1B1/3 inhibition.</td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20160128"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>Patients with moderate or severe hepatic impairment (Child-Pugh B or C). (<linkHtml href="#S4">4</linkHtml>)</item>
                           <item>OATP1B1/3 inhibitors, strong CYP3A inducers, and efavirenz. (<linkHtml href="#S4">4</linkHtml>) </item>
                           <item>If ZEPATIER is administered with ribavirin, the contraindications to ribavirin also apply. (<linkHtml href="#S4">4</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S5">
               <id root="82fa5a02-620e-4fb4-b8c7-f6bc22710b99"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20160128"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>ALT elevations: Perform hepatic laboratory testing prior to therapy, at treatment week 8, and as clinically indicated. For patients receiving 16 weeks of therapy, perform additional hepatic laboratory testing at treatment week 12. For ALT elevations on ZEPATIER, follow recommendations in full prescribing information. (<linkHtml href="#S5.1">5.1</linkHtml>) </item>
                           <item>Risk associated with ribavirin combination treatment: If ZEPATIER is administered with ribavirin, the warnings and precautions for ribavirin also apply. (<linkHtml href="#S5.2">5.2</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S5.1">
                     <id root="67f58a75-b72b-4332-8682-0353aa02a00c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1	Increased Risk of ALT Elevations</title>
                     <text>
                        <paragraph>During clinical trials with ZEPATIER with or without ribavirin, 1% of subjects experienced elevations of ALT from normal levels to greater than 5 times the upper limit of normal (ULN), generally at or after treatment week 8. ALT elevations were typically asymptomatic and most resolved with ongoing or completion of therapy. Higher rates of late ALT elevations occurred in the following subpopulations: female sex (2% [10/608]), Asian race (2% [4/164]), and age 65 years or older (2% [3/177]) <content styleCode="italics">[see <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>]</content>. </paragraph>
                        <paragraph>Hepatic laboratory testing should be performed prior to therapy, at treatment week 8, and as clinically indicated. For patients receiving 16 weeks of therapy, additional hepatic laboratory testing should be performed at treatment week 12.</paragraph>
                        <list listType="unordered">
                           <item>Patients should be instructed to consult their healthcare professional without delay if they have onset of fatigue, weakness, lack of appetite, nausea and vomiting, jaundice, or discolored feces.</item>
                           <item>Consider discontinuing ZEPATIER if ALT levels remain persistently greater than 10 times the ULN.</item>
                           <item>Discontinue ZEPATIER if ALT elevation is accompanied by signs or symptoms of liver inflammation or increasing conjugated bilirubin, alkaline phosphatase, or INR.</item>
                        </list>
                     </text>
                     <effectiveTime value="20160128"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.2">
                     <id root="50262295-99dc-4f93-bfaa-fac3b2ab20e7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2	Risks Associated with Ribavirin Combination Treatment</title>
                     <text>
                        <paragraph>If ZEPATIER is administered with ribavirin, the warnings and precautions for ribavirin, including the pregnancy avoidance warning, also apply to this combination regimen. Refer to the ribavirin prescribing information for a full list of warnings and precautions for ribavirin <content styleCode="italics">[see <linkHtml href="#S2.2">Dosage and Administration (2.2)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20160128"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.3">
                     <id root="393ae261-5c22-42bb-9b9a-a1c62128f673"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3	Risk of Adverse Reactions or Reduced Therapeutic Effect Due to Drug Interactions</title>
                     <text>
                        <paragraph>The concomitant use of ZEPATIER and certain drugs may result in known or potentially significant drug interactions, some of which may lead to:</paragraph>
                        <list listType="unordered">
                           <item>Possible clinically significant adverse reactions from greater exposure of concomitant drugs or components of ZEPATIER.</item>
                           <item>Significant decrease of elbasvir and grazoprevir plasma concentrations which may lead to reduced therapeutic effect of ZEPATIER and possible development of resistance.</item>
                        </list>
                        <paragraph>See <linkHtml href="#t2">Tables 2</linkHtml> and <linkHtml href="#t6">6</linkHtml> for steps to prevent or manage these known or potentially significant drug interactions, including dosing recommendations <content styleCode="italics">[see <linkHtml href="#S4">Contraindications (4)</linkHtml> and <linkHtml href="#S7.2">Drug Interactions (7.2)</linkHtml>]</content>. </paragraph>
                     </text>
                     <effectiveTime value="20160128"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S6">
               <id root="e979ac25-7c91-4f03-be44-bc6c332cf96f"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following adverse reaction is described below and elsewhere in the labeling: </paragraph>
                  <list listType="unordered">
                     <item>Increased Risk of ALT Elevations <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>].</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20160128"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>In subjects receiving ZEPATIER for 12 weeks, the most commonly reported adverse reactions of all intensity (greater than or equal to 5% in placebo-controlled trials) were fatigue, headache, and nausea. In subjects receiving ZEPATIER with ribavirin for 16 weeks, the most commonly reported adverse reactions of moderate or severe intensity (greater than or equal to 5%) were anemia and headache. (<linkHtml href="#S6.1">6.1</linkHtml>)</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Merck Sharp &amp; Dohme Corp., a subsidiary of Merck &amp; Co., Inc., at 1-877-888-4231 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S6.1">
                     <id root="933b8963-3add-4ca7-b3dc-3333a97b0db5"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.1	Clinical Trials Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>If ZEPATIER is administered with ribavirin, refer to the prescribing information for ribavirin for a description of ribavirin-associated adverse reactions. </paragraph>
                        <paragraph>The safety of ZEPATIER was assessed based on 2 placebo-controlled trials and 7 uncontrolled Phase 2 and 3 clinical trials in approximately 1700 subjects with chronic hepatitis C virus infection with compensated liver disease (with or without cirrhosis) <content styleCode="italics">[see <linkHtml href="#S14">Clinical Studies (14)</linkHtml>]</content>. </paragraph>
                     </text>
                     <effectiveTime value="20160128"/>
                     <component>
                        <section>
                           <id root="bb882737-12ae-422a-b0f1-5ac8b9c20027"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Adverse Reactions with ZEPATIER in Treatment-NaÃ¯ve Subjects</content>
                              </paragraph>
                              <paragraph>C-EDGE TN was a Phase 3 randomized, double-blind, placebo-controlled trial in 421 treatment-naÃ¯ve (TN) subjects with HCV infection who received ZEPATIER or placebo one tablet once daily for 12 weeks. Adverse reactions (all intensity) occurring in C-EDGE TN in at least 5% of subjects treated with ZEPATIER for 12 weeks are presented in <linkHtml href="#t3">Table 3</linkHtml>. In subjects treated with ZEPATIER who reported an adverse reaction, 73% had adverse reactions of mild severity. The type and severity of adverse reactions in subjects with compensated cirrhosis were comparable to those seen in subjects without cirrhosis. No subjects treated with ZEPATIER or placebo had serious adverse reactions. The proportion of subjects treated with ZEPATIER or placebo who permanently discontinued treatment due to adverse reactions was 1% in each group.</paragraph>
                              <table width="65%" ID="t3">
                                 <caption>Table 3: Adverse Reactions (All Intensity) Reported in â‰¥5% of Treatment-NaÃ¯ve Subjects with HCV Treated with ZEPATIER for 12 Weeks in C-EDGE TN</caption>
                                 <col width="32%" align="left" valign="top"/>
                                 <col width="34%" align="center" valign="top"/>
                                 <col width="34%" align="center" valign="top"/>
                                 <thead>
                                    <tr styleCode="Botrule">
                                       <th styleCode="Lrule Rrule"/>
                                       <th styleCode="Rrule" colspan="2">C-EDGE TN</th>
                                    </tr>
                                    <tr>
                                       <th styleCode="Lrule Rrule"/>
                                       <th styleCode="Rrule">ZEPATIER<br/>N=316<br/>%<br/>12 weeks</th>
                                       <th styleCode="Rrule">Placebo<br/>N=105<br/>%<br/>12 weeks</th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Fatigue</td>
                                       <td styleCode="Rrule">11%</td>
                                       <td styleCode="Rrule">10%</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Headache</td>
                                       <td styleCode="Rrule">10%</td>
                                       <td styleCode="Rrule">9%</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>C-EDGE COINFECTION was a Phase 3 open-label trial in 218 treatment-naÃ¯ve HCV/HIV co-infected subjects who received ZEPATIER one tablet once daily for 12 weeks. Adverse reactions (all intensity) reported in C-EDGE COINFECTION in at least 5% of subjects treated with ZEPATIER for 12 weeks were fatigue (7%), headache (7%), nausea (5%), insomnia (5%), and diarrhea (5%). No subjects reported serious adverse reactions or discontinued treatment due to adverse reactions. No subjects switched their antiretroviral therapy regimen due to loss of plasma HIV-1 RNA suppression. Median increase in CD4+ T-cell counts of 31 cells per mm<sup>3</sup> was observed at the end of 12 weeks of treatment. </paragraph>
                           </text>
                           <effectiveTime value="20160128"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="3022d288-0989-449e-9f41-ab51093feadc"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Adverse Reactions with ZEPATIER with or without Ribavirin in Treatment-Experienced Subjects </content>
                              </paragraph>
                              <paragraph>C-EDGE TE was a Phase 3 randomized, open-label trial in treatment-experienced (TE) subjects. Adverse reactions of moderate or severe intensity reported in C-EDGE TE in at least 2% of subjects treated with ZEPATIER one tablet once daily for 12 weeks or ZEPATIER one tablet once daily with ribavirin for 16 weeks are presented in <linkHtml href="#t4">Table 4</linkHtml>. No subjects treated with ZEPATIER without ribavirin for 12 weeks reported serious adverse reactions or discontinued treatment due to adverse reactions. The proportion of subjects treated with ZEPATIER with ribavirin for 16 weeks with serious adverse reactions was 1%. The proportion of subjects treated with ZEPATIER with ribavirin for 16 weeks who permanently discontinued treatment due to adverse reactions was 3%. The type and severity of adverse reactions in subjects with cirrhosis were comparable to those seen in subjects without cirrhosis. </paragraph>
                              <table width="65%" ID="t4">
                                 <caption>Table 4: Adverse Reactions (Moderate or Severe Intensity) Reported in â‰¥2% of PegIFN/RBV-Experienced Subjects with HCV Treated with ZEPATIER for 12 Weeks or ZEPATIER + Ribavirin for 16 Weeks in C-EDGE TE</caption>
                                 <col width="30%" align="left" valign="top"/>
                                 <col width="30%" align="center" valign="top"/>
                                 <col width="40%" align="center" valign="top"/>
                                 <thead>
                                    <tr styleCode="Botrule">
                                       <th styleCode="Lrule Rrule"/>
                                       <th styleCode="Rrule" colspan="2">C-EDGE TE</th>
                                    </tr>
                                    <tr>
                                       <th styleCode="Lrule Rrule"/>
                                       <th styleCode="Rrule">ZEPATIER<br/>N=105<br/>%<br/>12 weeks</th>
                                       <th styleCode="Rrule">ZEPATIER + Ribavirin<br/>N=106<br/>%<br/>16 weeks</th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Anemia</td>
                                       <td styleCode="Rrule">0%</td>
                                       <td styleCode="Rrule">8%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Headache</td>
                                       <td styleCode="Rrule">0%</td>
                                       <td styleCode="Rrule">6%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Fatigue</td>
                                       <td styleCode="Rrule">5%</td>
                                       <td styleCode="Rrule">4%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Dyspnea</td>
                                       <td styleCode="Rrule">0%</td>
                                       <td styleCode="Rrule">4%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Rash or Pruritus</td>
                                       <td styleCode="Rrule">0%</td>
                                       <td styleCode="Rrule">4%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Irritability </td>
                                       <td styleCode="Rrule">1%</td>
                                       <td styleCode="Rrule">3%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Abdominal pain</td>
                                       <td styleCode="Rrule">2%</td>
                                       <td styleCode="Rrule">2%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Depression</td>
                                       <td styleCode="Rrule">1%</td>
                                       <td styleCode="Rrule">2%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Arthralgia</td>
                                       <td styleCode="Rrule">0%</td>
                                       <td styleCode="Rrule">2%</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Diarrhea</td>
                                       <td styleCode="Rrule">2%</td>
                                       <td styleCode="Rrule">0%</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>The type and severity of adverse reactions with ZEPATIER with or without ribavirin in 10 treatment-experienced subjects with HCV/HIV co-infection were comparable to those reported in subjects without HIV co-infection. Median increase in CD4+ T-cell counts of 32 cells/mm<sup>3</sup> was observed at the end of 12 weeks of treatment with ZEPATIER alone. In subjects treated with ZEPATIER with ribavirin for 16 weeks, CD4+ T-cell counts decreased a median of 135 cells per mm<sup>3</sup> at the end of treatment. No subjects switched their antiretroviral therapy regimen due to loss of plasma HIV-1 RNA suppression. No subject experienced an AIDS-related opportunistic infection.</paragraph>
                              <paragraph>C-SALVAGE was a Phase 2 open-label trial in 79 PegIFN/RBV/PI-experienced subjects. Adverse reactions of moderate or severe intensity reported in C-SALVAGE in at least 2% of subjects treated with ZEPATIER once daily with ribavirin for 12 weeks were fatigue (3%) and insomnia (3%). No subjects reported serious adverse reactions or discontinued treatment due to adverse reactions.</paragraph>
                           </text>
                           <effectiveTime value="20160128"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="9e802a45-0eba-4a8c-a064-6263077b196c"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Adverse Reactions with ZEPATIER in Subjects with Severe Renal Impairment including Subjects on Hemodialysis</content>
                              </paragraph>
                              <paragraph>The safety of elbasvir and grazoprevir in comparison to placebo in subjects with severe renal impairment (Stage 4 or Stage 5 chronic kidney disease, including subjects on hemodialysis) and chronic hepatitis C virus infection with compensated liver disease (with or without cirrhosis) was assessed in 235 subjects (C-SURFER) <content styleCode="italics">[see <linkHtml href="#S14.4">Clinical Studies (14.4)</linkHtml>]</content>. The adverse reactions (all intensity) occurring in at least 5% of subjects treated with ZEPATIER for 12 weeks are presented in <linkHtml href="#t5">Table 5</linkHtml>. In subjects treated with ZEPATIER who reported an adverse reaction, 76% had adverse reactions of mild severity. The proportion of subjects treated with ZEPATIER or placebo with serious adverse reactions was less than 1% in each treatment arm, and less than 1% and 3% of subjects, respectively, permanently discontinued treatment due to adverse reactions in each treatment arm. </paragraph>
                              <table width="65%" ID="t5">
                                 <caption>Table 5: Adverse Reactions (All Intensity) Reported in â‰¥5% of Treatment-NaÃ¯ve or PegIFN/RBV-Experienced Subjects with Stage 4 or 5 Chronic Kidney Disease and HCV Treated with ZEPATIER for 12 Weeks in C-SURFER</caption>
                                 <col width="32%" align="left" valign="top"/>
                                 <col width="34%" align="center" valign="top"/>
                                 <col width="34%" align="center" valign="top"/>
                                 <thead>
                                    <tr>
                                       <th styleCode="Lrule Rrule"/>
                                       <th styleCode="Rrule">ZEPATIER<br/>N=122<br/>%<br/>12 weeks</th>
                                       <th styleCode="Rrule">Placebo<br/>N=113<br/>%<br/>12 weeks</th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Nausea</td>
                                       <td styleCode="Rrule">11%</td>
                                       <td styleCode="Rrule">8%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Headache</td>
                                       <td styleCode="Rrule">11%</td>
                                       <td styleCode="Rrule">5%</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Fatigue</td>
                                       <td styleCode="Rrule">5%</td>
                                       <td styleCode="Rrule">8%</td>
                                    </tr>
                                 </tbody>
                              </table>
                           </text>
                           <effectiveTime value="20160128"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="24a22cec-b4fa-4b9e-ad0c-774d38cc61bb"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Laboratory Abnormalities in Subjects Receiving ZEPATIER with or without Ribavirin</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20160128"/>
                           <component>
                              <section>
                                 <id root="a5ce5fea-40c1-46c3-8236-c0147dd5985d"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Serum ALT Elevations </content>
                                    </paragraph>
                                    <paragraph>During clinical trials with ZEPATIER with or without ribavirin, regardless of treatment duration, 1% (12/1599) of subjects experienced elevations of ALT from normal levels to greater than 5 times the ULN, generally at or after treatment week 8 (mean onset time 10 weeks, range 6-12 weeks). These late ALT elevations were typically asymptomatic. Most late ALT elevations resolved with ongoing therapy with ZEPATIER or after completion of therapy <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>. The frequency of late ALT elevations was higher in subjects with higher grazoprevir plasma concentrations <content styleCode="italics">[see <linkHtml href="#S7.1">Drug Interactions (7.1)</linkHtml> and <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>. The incidence of late ALT elevations was not affected by treatment duration. Cirrhosis was not a risk factor for late ALT elevations. </paragraph>
                                 </text>
                                 <effectiveTime value="20160128"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="72299006-70aa-4713-98eb-7e82841693fe"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Serum Bilirubin Elevations</content>
                                    </paragraph>
                                    <paragraph>During clinical trials with ZEPATIER with or without ribavirin, regardless of treatment duration, elevations in bilirubin at greater than 2.5 times ULN were observed in 6% of subjects receiving ZEPATIER with ribavirin compared to less than 1% in those receiving ZEPATIER alone. These bilirubin increases were predominately indirect and generally observed in association with ribavirin co-administration. Bilirubin elevations were typically not associated with serum ALT elevations.</paragraph>
                                 </text>
                                 <effectiveTime value="20160128"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="f5f1b9f2-e82b-4bf4-ae4a-fece987d9eac"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Decreased Hemoglobin</content>
                                    </paragraph>
                                    <paragraph>During clinical trials with ZEPATIER with or without ribavirin, the mean change from baseline in hemoglobin levels in subjects treated with ZEPATIER for 12 weeks was â€“0.3 g per dL and with ZEPATIER with ribavirin for 16 weeks was approximately â€“2.2 g per dL. Hemoglobin declined during the first 8 weeks of treatment, remained low during the remainder of treatment, and normalized to baseline levels during follow-up. Less than 1% of subjects treated with ZEPATIER with ribavirin had hemoglobin levels decrease to less than 8.5 g per dL during treatment. No subjects treated with ZEPATIER alone had a hemoglobin level less than 8.5 g per dL. </paragraph>
                                 </text>
                                 <effectiveTime value="20160128"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S7">
               <id root="c36de825-7954-4be6-99f6-69a5ba3f1b0b"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <effectiveTime value="20160128"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>Co-administration of ZEPATIER with moderate CYP3A inducers is not recommended as they may decrease the plasma concentration of ZEPATIER. (<linkHtml href="#S7">7</linkHtml>)</item>
                           <item>Co-administration of ZEPATIER with certain strong CYP3A inhibitors is not recommended as they may increase the plasma concentration of ZEPATIER. (<linkHtml href="#S7">7</linkHtml>)</item>
                           <item>Consult the full prescribing information prior to and during treatment for potential drug interactions. (<linkHtml href="#S4">4</linkHtml>, <linkHtml href="#S5.3">5.3</linkHtml>, <linkHtml href="#S7">7</linkHtml>, <linkHtml href="#S12.3">12.3</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S7.1">
                     <id root="33f0af9d-f6e8-48cc-a65f-4b9c98acd3a2"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.1	Potential for Drug Interactions</title>
                     <text>
                        <paragraph>Grazoprevir is a substrate of OATP1B1/3 transporters. Co-administration of ZEPATIER with drugs that inhibit OATP1B1/3 transporters may result in a significant increase in the plasma concentrations of grazoprevir. As such, co-administration of ZEPATIER with OATP1B1/3 inhibitors is contraindicated <content styleCode="italics">[see <linkHtml href="#S4">Contraindications (4)</linkHtml>, <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>], and <linkHtml href="#t2">Table 2</linkHtml>
                           </content>.</paragraph>
                        <paragraph>Elbasvir and grazoprevir are substrates of CYP3A and P-gp, but the role of intestinal P-gp in the absorption of elbasvir and grazoprevir appears to be minimal. Co-administration of moderate or strong inducers of CYP3A with ZEPATIER may decrease elbasvir and grazoprevir plasma concentrations, leading to reduced therapeutic effect of ZEPATIER. Co-administration of ZEPATIER with strong CYP3A inducers or efavirenz is contraindicated <content styleCode="italics">[see <linkHtml href="#S4">Contraindications (4)</linkHtml>, <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>], and <linkHtml href="#t2">Table 2</linkHtml>.</content> Co-administration of ZEPATIER with moderate CYP3A inducers is not recommended <content styleCode="italics">[see <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>, <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>], and <linkHtml href="#t6">Table 6</linkHtml>.</content> Co-administration of ZEPATIER with strong CYP3A inhibitors may increase elbasvir and grazoprevir concentrations. Co-administration of ZEPATIER with certain strong CYP3A inhibitors is not recommended <content styleCode="italics">[see <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>, <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>], and <linkHtml href="#t6">Table 6</linkHtml>
                           </content>. </paragraph>
                     </text>
                     <effectiveTime value="20160128"/>
                  </section>
               </component>
               <component>
                  <section ID="S7.2">
                     <id root="2869f8a2-a008-475f-af63-0eba28f43674"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.2	Established and other Potentially Significant Drug Interactions</title>
                     <text>
                        <paragraph>If dose adjustments of concomitant medications are made due to treatment with ZEPATIER, doses should be readjusted after administration of ZEPATIER is completed. </paragraph>
                        <paragraph>
                           <linkHtml href="#t6">Table 6</linkHtml> provides a listing of established or potentially clinically significant drug interactions. The drug interactions described are based on studies conducted with either ZEPATIER, the components of ZEPATIER (elbasvir [EBR] and grazoprevir [GZR]) as individual agents, or are predicted drug interactions that may occur with ZEPATIER <content styleCode="italics">[see <linkHtml href="#S4">Contraindications (4)</linkHtml>, <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>, and <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>.</paragraph>
                        <table width="90%" ID="t6">
                           <caption>Table 6: Potentially Significant Drug Interactions: Alteration in Dose May Be Recommended Based on Results from Drug Interaction Studies or Predicted Interactions<footnote ID="t6f1">This table is not all inclusive.</footnote>
                           </caption>
                           <col width="25%" align="left" valign="top"/>
                           <col width="20%" align="left" valign="top"/>
                           <col width="55%" align="left" valign="top"/>
                           <thead>
                              <tr>
                                 <th styleCode="Lrule Rrule" align="center">Concomitant Drug Class: Drug Name</th>
                                 <th styleCode="Rrule" align="center">Effect on Concentration<footnote ID="t6f2">â†“ = decrease, â†‘ = increase</footnote>
                                 </th>
                                 <th styleCode="Rrule" align="center">Clinical Comment</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="bold">Antibiotics</content>:<br/>nafcillin</td>
                                 <td styleCode="Rrule">â†“ EBR <br/>â†“ GZR</td>
                                 <td styleCode="Rrule">Co-administration of ZEPATIER with nafcillin, a moderate CYP3A inducer, may decrease EBR and GZR concentrations, leading to reduced therapeutic effect of ZEPATIER. Co-administration is not recommended.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="bold">Antifungals:</content>
                                    <br/>ketoconazole<footnote ID="t6f3">These interactions have been studied in healthy adults.</footnote>
                                 </td>
                                 <td styleCode="Rrule">â†‘ EBR<br/>â†‘ GZR</td>
                                 <td styleCode="Rrule">Concomitant use of systemic ketoconazole and ZEPATIER increases grazoprevir exposure and may increase the overall risk of hepatotoxicity; co-administration of ketoconazole is not recommended.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="bold">Endothelin Antagonists:</content>
                                    <br/>bosentan</td>
                                 <td styleCode="Rrule">â†“ EBR <br/>â†“ GZR</td>
                                 <td styleCode="Rrule">Co-administration of ZEPATIER with bosentan, a moderate CYP3A inducer, may decrease EBR and GZR concentrations, leading to reduced therapeutic effect of ZEPATIER. Co-administration is not recommended.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="bold">Immunosuppressants:</content>
                                    <br/>tacrolimus<footnoteRef IDREF="t6f3"/>
                                 </td>
                                 <td styleCode="Rrule">â†‘ tacrolimus</td>
                                 <td styleCode="Rrule">Co-administration of ZEPATIER with systemic tacrolimus increases the concentrations of tacrolimus. Frequent monitoring of tacrolimus whole blood concentrations, changes in renal function, and tacrolimus-associated adverse events upon the initiation of co-administration is recommended.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" colspan="3">
                                    <content styleCode="bold">HIV Medications:</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">etravirine</td>
                                 <td styleCode="Rrule">â†“ EBR <br/>â†“ GZR</td>
                                 <td styleCode="Rrule">Co-administration of ZEPATIER with etravirine, a moderate CYP3A inducer, may decrease EBR and GZR concentrations, leading to reduced therapeutic effect of ZEPATIER. Co-administration is not recommended.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">elvitegravir/ cobicistat/ emtricitabine/ tenofovir (disoproxil fumarate or alafenamide)</td>
                                 <td styleCode="Rrule">â†‘ EBR <br/>â†‘ GZR</td>
                                 <td styleCode="Rrule">Co-administration of ZEPATIER with these cobicistat-containing regimens may increase the concentrations of EBR and GZR. Co-administration is not recommended.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" colspan="3">
                                    <content styleCode="bold">HMG-CoA Reductase Inhibitors<footnote ID="t6f4">
                                          <content styleCode="italics">See <linkHtml href="#S7.3">Drug Interactions (7.3)</linkHtml>
                                          </content> for a list of HMG Co-A reductase inhibitors without clinically relevant interactions with ZEPATIER.</footnote>:</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">atorvastatin<footnoteRef IDREF="t6f3"/>
                                 </td>
                                 <td styleCode="Rrule">â†‘ atorvastatin</td>
                                 <td styleCode="Rrule">Co-administration of EBR and GZR with atorvastatin increases the concentrations of atorvastatin. The dose of atorvastatin should not exceed a daily dose of 20 mg when co-administered with ZEPATIER.<footnoteRef IDREF="t6f4"/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">rosuvastatin<footnoteRef IDREF="t6f3"/>
                                 </td>
                                 <td styleCode="Rrule">â†‘ rosuvastatin</td>
                                 <td styleCode="Rrule">Co-administration of EBR and GZR with rosuvastatin increases the concentrations of rosuvastatin. The dose of rosuvastatin should not exceed a daily dose of 10 mg when co-administered with ZEPATIER.<footnoteRef IDREF="t6f4"/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">fluvastatin<br/>lovastatin<br/>simvastatin</td>
                                 <td styleCode="Rrule">â†‘ fluvastatin<br/>â†‘ lovastatin<br/>â†‘ simvastatin</td>
                                 <td styleCode="Rrule">Co-administration of ZEPATIER with these statins has not been studied but may increase the concentrations of these statins. Statin-associated adverse events such as myopathy should be closely monitored. The lowest necessary dose should be used when co-administered with ZEPATIER.<footnoteRef IDREF="t6f4"/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="bold">Wakefulness-Promoting Agents:</content>
                                    <br/>modafinil</td>
                                 <td styleCode="Rrule">â†“ EBR <br/>â†“ GZR</td>
                                 <td styleCode="Rrule">Co-administration of ZEPATIER with modafinil, a moderate CYP3A inducer, may decrease EBR and GZR concentrations, leading to reduced therapeutic effect of ZEPATIER. Co-administration is not recommended.</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20160128"/>
                  </section>
               </component>
               <component>
                  <section ID="S7.3">
                     <id root="fd5a07d6-6055-430d-845e-7341a807f6fe"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.3	Drugs without Clinically Significant Interactions with ZEPATIER</title>
                     <text>
                        <paragraph>The interaction between the components of ZEPATIER (elbasvir or grazoprevir) or ZEPATIER and the following drugs were evaluated in clinical studies, and no dose adjustments are needed when ZEPATIER is used with the following drugs individually: acid reducing agents (proton pump inhibitors, H2 blockers, antacids), buprenorphine/naloxone, digoxin, dolutegravir, methadone, mycophenolate mofetil, oral contraceptive pills, phosphate binders, pitavastatin, pravastatin, prednisone, raltegravir, ribavirin, rilpivirine, tenofovir disoproxil fumarate, and sofosbuvir <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>. </paragraph>
                        <paragraph>No clinically relevant drug-drug interaction is expected when ZEPATIER is co-administered with abacavir, emtricitabine, entecavir, and lamivudine.</paragraph>
                     </text>
                     <effectiveTime value="20160128"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S8">
               <id root="95fbbf2a-6d73-4740-aa21-287c3ca514e3"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20160128"/>
               <component>
                  <section ID="S8.1">
                     <id root="c517782c-244d-4d8a-a818-5e1c72c94bc3"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <effectiveTime value="20160128"/>
                     <component>
                        <section>
                           <id root="faab249c-11e7-4900-a8a2-7222b81d2f0e"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics underline">Risk Summary </content>
                              </paragraph>
                              <paragraph>No adequate human data are available to establish whether or not ZEPATIER poses a risk to pregnancy outcomes. In animal reproduction studies, no evidence of adverse developmental outcomes was observed with the components of ZEPATIER (elbasvir or grazoprevir) at exposures greater than those in humans at the recommended human dose (RHD) <content styleCode="italics">[see <linkHtml href="#Data">Data</linkHtml> in (8.1)]</content>. During organogenesis in the rat and rabbit, systemic exposures (AUC) were approximately 10 and 18 times (for elbasvir) and 117 and 41 times (for grazoprevir), respectively, the exposure in humans at the RHD. In rat pre/postnatal developmental studies, maternal systemic exposures (AUC) to elbasvir and grazoprevir were approximately 10 and 78 times, respectively, the exposure in humans at the RHD.</paragraph>
                              <paragraph>The background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.</paragraph>
                              <paragraph>If ZEPATIER is administered with ribavirin, the combination regimen is contraindicated in pregnant women and in men whose female partners are pregnant. Refer to the ribavirin prescribing information for more information on use in pregnancy.</paragraph>
                           </text>
                           <effectiveTime value="20160128"/>
                        </section>
                     </component>
                     <component>
                        <section ID="Data">
                           <id root="a333661d-3ebe-49ea-8854-8e638a01953d"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics underline">Data</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20160128"/>
                           <component>
                              <section>
                                 <id root="ef18274b-0fd0-4f3b-aeb2-00828d5374bc"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Animal Data </content>
                                    </paragraph>
                                 </text>
                                 <effectiveTime value="20160128"/>
                                 <component>
                                    <section>
                                       <id root="89c4cc0b-f17c-488f-b0a1-062fd3fbc48b"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <text>
                                          <paragraph>
                                             <content styleCode="italics">Elbasvir:</content> Elbasvir was administered orally at up to 1000 mg/kg/day to pregnant rats and rabbits on gestation days 6 to 20 and 7 to 20, respectively, and also to rats on gestation day 6 to lactation/post-partum day 20. No effects on embryo-fetal (rats and rabbits) or pre/postnatal (rats) development were observed at up to the highest dose tested. Systemic exposures (AUC) to elbasvir were approximately 10 (rats) and 18 (rabbits) times the exposure in humans at the RHD. In both species, elbasvir has been shown to cross the placenta, with fetal plasma concentrations of up to 0.8% (rabbits) and 2.2% (rats) that of maternal concentrations observed on gestation day 20. </paragraph>
                                       </text>
                                       <effectiveTime value="20160128"/>
                                    </section>
                                 </component>
                                 <component>
                                    <section>
                                       <id root="c510fbc1-d79a-4457-89d3-fdb45429813a"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <text>
                                          <paragraph>
                                             <content styleCode="italics">Grazoprevir:</content> Grazoprevir was administered to pregnant rats (oral doses up to 400 mg/kg/day) and rabbits (intravenous doses up to 100 mg/kg/day) on gestation days 6 to 20 and 7 to 20, respectively, and also to rats (oral doses up to 400 mg/kg/day) on gestation day 6 to lactation/post-partum day 20. No effects on embryo-fetal (rats and rabbits) or pre/postnatal (rats) development were observed at up to the highest dose tested. Systemic exposures (AUC) to grazoprevir were â‰¥78 (rats) and 41 (rabbits) times the exposure in humans at the RHD. In both species, grazoprevir has been shown to cross the placenta, with fetal plasma concentrations of up to 7% (rabbits) and 89% (rats) that of maternal concentrations observed on gestation day 20. </paragraph>
                                       </text>
                                       <effectiveTime value="20160128"/>
                                    </section>
                                 </component>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.2">
                     <id root="ed7de82c-648b-4567-8fd2-815ca8bc7019"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2	Lactation</title>
                     <effectiveTime value="20160128"/>
                     <component>
                        <section>
                           <id root="f70ca0dd-43b1-437c-abf1-d118847d3a56"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics underline">Risk Summary </content>
                              </paragraph>
                              <paragraph>It is not known whether ZEPATIER is present in human breast milk, affects human milk production, or has effects on the breastfed infant. When administered to lactating rats, the components of ZEPATIER (elbasvir and grazoprevir) were present in milk, without effects on growth and development observed in nursing pups <content styleCode="italics">[see <linkHtml href="#Data1">Data</linkHtml> in (8.2)]</content>.</paragraph>
                              <paragraph>The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for ZEPATIER and any potential adverse effects on the breastfed child from ZEPATIER or from the underlying maternal condition. </paragraph>
                              <paragraph>If ZEPATIER is administered with ribavirin, the information for ribavirin with regard to nursing mothers also applies to this combination regimen. Refer to the ribavirin prescribing information for information on use during lactation.</paragraph>
                           </text>
                           <effectiveTime value="20160128"/>
                        </section>
                     </component>
                     <component>
                        <section ID="Data1">
                           <id root="630ba2fa-7c80-4383-a771-d8ae071bcccf"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics underline">Data</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20160128"/>
                           <component>
                              <section>
                                 <id root="a4b27212-42ac-4829-ba5d-19ce4401610b"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Elbasvir:</content> No effects of elbasvir on growth and postnatal development were observed in nursing pups at up to the highest dose tested <content styleCode="italics">[see <linkHtml href="#Data">Data</linkHtml> in (8.1)]</content>. Maternal systemic exposure (AUC) to elbasvir was approximately 10 times the exposure in humans at the RHD. Elbasvir was excreted into the milk of lactating rats following oral administration (1000 mg/kg/day) from gestation day 6 to lactation day 14, with milk concentrations approximately 4 times that of maternal plasma concentrations observed 2 hours post-dose on lactation day 14. </paragraph>
                                 </text>
                                 <effectiveTime value="20160128"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="0a28ef55-81d3-48d2-9088-4a987f3a4ca8"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Grazoprevir:</content> No effects of grazoprevir on growth and postnatal development were observed in nursing pups at up to the highest dose tested <content styleCode="italics">[see <linkHtml href="#Data">Data</linkHtml> in (8.1)]</content>. Maternal systemic exposure (AUC) to grazoprevir was approximately 78 times the exposure in humans at the RHD. Grazoprevir was excreted into the milk of lactating rats following oral administration (up to 400 mg/kg/day) from gestation day 6 to lactation day 14, with milk concentrations of 54 and 87% that of maternal plasma concentrations observed 2 and 8 hours post-dose, respectively, on lactation day 14. </paragraph>
                                 </text>
                                 <effectiveTime value="20160128"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.3">
                     <id root="382d58e0-d75a-4d6f-8785-fc62b2ecd544"/>
                     <code code="77291-3" codeSystem="2.16.840.1.113883.6.1" displayName="FEMALES &amp; MALES OF REPRODUCTIVE POTENTIAL SECTION"/>
                     <title>8.3	Females and Males of Reproductive Potential</title>
                     <text>
                        <paragraph>If ZEPATIER is administered with ribavirin, the information for ribavirin with regard to pregnancy testing, contraception, and infertility also applies to this combination regimen. Refer to ribavirin prescribing information for additional information.</paragraph>
                     </text>
                     <effectiveTime value="20160128"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.4">
                     <id root="f1fd68ed-f049-4bbd-9e83-c3ab18d3eaf1"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>Safety and efficacy in pediatric patients have not been established in pediatric patients less than 18 years of age.</paragraph>
                     </text>
                     <effectiveTime value="20160128"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.5">
                     <id root="afe095dd-e74b-49f0-9d15-a9a5065e3fa2"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>Clinical trials of ZEPATIER with or without ribavirin included 187 subjects aged 65 years and over. Higher elbasvir and grazoprevir plasma concentrations were observed in subjects aged 65 years and over. A higher rate of late ALT elevations was observed in subjects aged 65 years and over in clinical trials <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>. However, no dosage adjustment of ZEPATIER is recommended in geriatric patients <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20160128"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.6">
                     <id root="9fe4f2ad-38fa-4b8c-b3f4-66c49f090ebf"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.6	Gender </title>
                     <text>
                        <paragraph>Higher elbasvir and grazoprevir plasma concentrations were observed in females compared to males. Females experienced a higher rate of late ALT elevations in clinical trials <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>. However, no dose adjustment of ZEPATIER is recommended based on gender <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20160128"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.7">
                     <id root="b6384c2d-b011-461e-848f-c50565711d20"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.7	Race</title>
                     <text>
                        <paragraph>Higher elbasvir and grazoprevir plasma concentrations were observed in Asians compared to Caucasians. Asians experienced a higher rate of late ALT elevations in clinical trials <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>. However, no dose adjustment of ZEPATIER is recommended based on race/ethnicity <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20160128"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.8">
                     <id root="9a5a54b2-fd8c-4616-a928-0101d5fbacdc"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.8	Renal Impairment</title>
                     <text>
                        <paragraph>No dosage adjustment of ZEPATIER is recommended in patients with any degree of renal impairment including patients receiving hemodialysis <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>. Administer ZEPATIER with or without ribavirin according to recommendations in <linkHtml href="#t1">Table 1</linkHtml>
                           <content styleCode="italics">[see <linkHtml href="#S2.2">Dosage and Administration (2.2</linkHtml>, <linkHtml href="#S2.3">2.3)</linkHtml>].</content> Refer to the prescribing information for ribavirin tablets for renal dosage adjustment of ribavirin in patients with CrCl less than or equal to 50 mL per minute. </paragraph>
                     </text>
                     <effectiveTime value="20160128"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.9">
                     <id root="370314a1-7ecd-46c4-9849-0eb05224dc07"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.9	Hepatic Impairment</title>
                     <text>
                        <paragraph>No dosage adjustment of ZEPATIER is recommended in patients with mild hepatic impairment (Child-Pugh A). ZEPATIER is contraindicated in patients with moderate hepatic impairment (Child-Pugh B) due to the lack of clinical safety and efficacy experience in HCV-infected Child-Pugh B patients, and in patients with severe hepatic impairment (Child-Pugh C) due to a 12-fold increase in grazoprevir exposure in non-HCV infected Child-Pugh C subjects <content styleCode="italics">[see <linkHtml href="#S2.4">Dosage and Administration (2.4)</linkHtml>, <linkHtml href="#S4">Contraindications (4)</linkHtml>, and <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>].</content>
                        </paragraph>
                        <paragraph>The safety and efficacy of ZEPATIER have not been established in patients awaiting liver transplant or in liver transplant recipients. </paragraph>
                     </text>
                     <effectiveTime value="20160128"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S10">
               <id root="7918e913-7c5f-4c6f-abce-0cc9593fb6f1"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph>Human experience of overdose with ZEPATIER is limited. No specific antidote is available for overdose with ZEPATIER. In case of overdose, it is recommended that the patient be monitored for any signs or symptoms of adverse reactions and appropriate symptomatic treatment instituted. </paragraph>
                  <paragraph>Hemodialysis does not remove elbasvir or grazoprevir since elbasvir and grazoprevir are highly bound to plasma protein <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>. </paragraph>
               </text>
               <effectiveTime value="20160128"/>
            </section>
         </component>
         <component>
            <section ID="S11">
               <id root="3499e7df-1378-4023-a3fe-a91c8ef1f3da"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>ZEPATIER is a fixed-dose combination tablet containing elbasvir and grazoprevir for oral administration.</paragraph>
                  <paragraph>Elbasvir is an HCV NS5A inhibitor, and grazoprevir is an HCV NS3/4A protease inhibitor.</paragraph>
                  <paragraph>Each tablet contains 50 mg elbasvir and 100 mg grazoprevir. The tablets include the following inactive ingredients: colloidal silicon dioxide, copovidone, croscarmellose sodium, hypromellose, lactose monohydrate, magnesium stearate, mannitol, microcrystalline cellulose, sodium chloride, sodium lauryl sulfate, and vitamin E polyethylene glycol succinate. The tablets are film-coated with a coating material containing the following inactive ingredients: carnauba wax, ferrosoferric oxide, hypromellose, iron oxide red, iron oxide yellow, lactose monohydrate, titanium dioxide, and triacetin.</paragraph>
               </text>
               <effectiveTime value="20160128"/>
               <component>
                  <section>
                     <id root="74c97009-4553-4363-bac2-8dfd74abaef6"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Elbasvir: </content>
                        </paragraph>
                        <paragraph>The IUPAC name for elbasvir is Dimethyl <content styleCode="italics">N</content>,<content styleCode="italics">N'</content>-([(6<content styleCode="italics">S</content>)-6-phenylindolo[1,2-<content styleCode="italics">c</content>][1,3]benzoxazine-3,10-diyl]bis{1<content styleCode="italics">H</content>-imidazole-5,2-diyl-(2<content styleCode="italics">S</content>)-pyrrolidine-2,1-diyl[(2<content styleCode="italics">S</content>)-3-methyl-1-oxobutane-1,2-diyl]})dicarbamate.</paragraph>
                        <paragraph>It has a molecular formula of C<sub>49</sub>H<sub>55</sub>N<sub>9</sub>O<sub>7</sub> and a molecular weight of 882.02. It has the following structural formula:</paragraph>
                        <paragraph>
                           <renderMultiMedia referencedObject="MM1"/>
                        </paragraph>
                        <paragraph>Elbasvir is practically insoluble in water (less than 0.1 mg per mL) and very slightly soluble in ethanol (0.2 mg per mL), but is very soluble in ethyl acetate and acetone.</paragraph>
                     </text>
                     <effectiveTime value="20160128"/>
                     <component>
                        <observationMedia ID="MM1">
                           <text>Chemical Structure</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="zepatier-01.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="6c19925d-8b27-40d0-9a7d-bddcdde61927"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Grazoprevir: </content>
                        </paragraph>
                        <paragraph>The IUPAC name for grazoprevir is (1a<content styleCode="italics">R</content>,5<content styleCode="italics">S</content>,8<content styleCode="italics">S</content>,10<content styleCode="italics">R</content>,22a<content styleCode="italics">R</content>)-<content styleCode="italics">N</content>-[(1<content styleCode="italics">R</content>,2<content styleCode="italics">S</content>)-1-[(Cyclopropylsulfonamido)carbonyl]-2-ethenylcyclopropyl]-14-methoxy-5-(2-methylpropan-2-yl)-3,6-dioxo-1,1a,3,4,5,6,9,10,18,19,20,21,22,22a-tetradecahydro-8<content styleCode="italics">H</content>-7,10-methanocyclopropa[18,19][1,10,3,6]dioxadiazacyclononadecino[11,12-<content styleCode="italics">b</content>]quinoxaline-8-carboxamide.</paragraph>
                        <paragraph>It has a molecular formula of C<sub>38</sub>H<sub>50</sub>N<sub>6</sub>O<sub>9</sub>S and a molecular weight of 766.90. It has the following structural formula:</paragraph>
                        <paragraph>
                           <renderMultiMedia referencedObject="MM2"/>
                        </paragraph>
                        <paragraph>Grazoprevir is practically insoluble in water (less than 0.1 mg per mL) but is freely soluble in ethanol and some organic solvents (e.g., acetone, tetrahydrofuran and N,N-dimethylformamide).</paragraph>
                     </text>
                     <effectiveTime value="20160128"/>
                     <component>
                        <observationMedia ID="MM2">
                           <text>Chemical Structure</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="zepatier-02.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S12">
               <id root="2c0ea411-6cf0-4ea4-9376-6d239def8eb4"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20160128"/>
               <component>
                  <section ID="S12.1">
                     <id root="07d0e727-3843-4b0d-9e6b-55a282adce98"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1	Mechanism of Action</title>
                     <text>
                        <paragraph>ZEPATIER is a fixed-dose combination of elbasvir and grazoprevir which are direct-acting antiviral agents against the hepatitis C virus <content styleCode="italics">[see <linkHtml href="#S12.4">Microbiology (12.4)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20160128"/>
                  </section>
               </component>
               <component>
                  <section ID="S12.2">
                     <id root="b35f44fb-89c6-47df-9e18-88c120a2ae2d"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <effectiveTime value="20160128"/>
                     <component>
                        <section>
                           <id root="a87efa4e-3d7d-47aa-b32c-1edbad5dd539"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Cardiac Electrophysiology </content>
                              </paragraph>
                              <paragraph>Thorough QT studies have been conducted for elbasvir and grazoprevir. </paragraph>
                              <paragraph>The effect of elbasvir 700 mg on QTc interval was evaluated in a randomized, single-dose, placebo- and active-controlled (moxifloxacin 400 mg) 3-period crossover thorough QT trial in 42 healthy subjects. At a concentration 3 to 4 times the therapeutic concentration, elbasvir does not prolong QTc to any clinically relevant extent.</paragraph>
                              <paragraph>The effect of grazoprevir 1600 mg (16 times the approved dose) on QTc interval was evaluated in a randomized, single-dose, placebo- and active-controlled (moxifloxacin 400 mg) 3-period crossover thorough QT trial in 41 healthy subjects. At a concentration 40 times the therapeutic concentration, grazoprevir does not prolong QTc to any clinically relevant extent.</paragraph>
                           </text>
                           <effectiveTime value="20160128"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S12.3">
                     <id root="548b99bf-572a-4615-afc9-3cb3c34769fe"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>The pharmacokinetic properties of elbasvir and grazoprevir have been evaluated in non-HCV-infected adult subjects and in HCV-infected adult subjects. Elbasvir pharmacokinetics were similar in healthy subjects and HCV-infected subjects and were approximately dose-proportional over the range of 5-100 mg once daily. Grazoprevir oral exposures are approximately 2-fold greater in HCV-infected subjects as compared to healthy subjects. Grazoprevir pharmacokinetics increased in a greater than dose-proportional manner over the range of 10-800 mg once daily in HCV-infected subjects. Ribavirin co-administration with ZEPATIER had no clinically relevant impact on plasma AUC and C<sub>max</sub> of elbasvir and grazoprevir compared to administration of ZEPATIER alone. The geometric mean steady-state pharmacokinetic parameter values for elbasvir and grazoprevir in non-cirrhotic HCV-infected subjects are provided in <linkHtml href="#t7">Table 7</linkHtml>. Following once daily administration of ZEPATIER to HCV-infected subjects, elbasvir and grazoprevir reached steady state within approximately 6 days.</paragraph>
                        <table width="75%" ID="t7">
                           <caption>Table 7: Geometric Mean (90% Confidence Interval) for Elbasvir and Grazoprevir Steady State Pharmacokinetic Parameter Values in Non-Cirrhotic HCV-Infected Subjects Estimated Based on Population Pharmacokinetic Modeling</caption>
                           <col width="15%" align="center" valign="bottom"/>
                           <col width="30%" align="center" valign="bottom"/>
                           <col width="25%" align="center" valign="bottom"/>
                           <col width="30%" align="center" valign="bottom"/>
                           <thead>
                              <tr styleCode="Botrule">
                                 <th styleCode="Rrule Lrule" rowspan="2"/>
                                 <th styleCode="Rrule" colspan="3">Geometric Mean (90% Confidence Interval)</th>
                              </tr>
                              <tr>
                                 <th styleCode="Rrule Lrule">AUC<sub>0-24</sub> (ngâ€¢hr/mL)</th>
                                 <th styleCode="Rrule">C<sub>max</sub> (ng/mL)</th>
                                 <th styleCode="Rrule">C<sub>24</sub> (ng/mL)</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Rrule Lrule">Elbasvir</td>
                                 <td styleCode="Rrule">1920 (1880, 1960)</td>
                                 <td styleCode="Rrule">121 (118, 123)</td>
                                 <td styleCode="Rrule">48.4 (47.3, 49.6)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule">Grazoprevir</td>
                                 <td styleCode="Rrule">1420 (1400, 1530)</td>
                                 <td styleCode="Rrule">165 (161, 176)</td>
                                 <td styleCode="Rrule">18.0 (17.8,19.9)</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20160128"/>
                     <component>
                        <section>
                           <id root="08866578-8af5-4ff3-994f-97be989e7b18"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Absorption</content>
                              </paragraph>
                              <paragraph>Following administration of ZEPATIER to HCV-infected subjects, elbasvir peak concentrations occur at a median T<sub>max</sub> of 3 hours (range of 3 to 6 hours); grazoprevir peak concentrations occur at a median T<sub>max</sub> of 2 hours (range of 30 minutes to 3 hours). </paragraph>
                           </text>
                           <effectiveTime value="20160128"/>
                           <component>
                              <section>
                                 <id root="71e8f89b-653a-41f0-812a-c8e2ce6a737a"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Effect of Food</content>
                                    </paragraph>
                                    <paragraph>Relative to fasting conditions, the administration of a single dose of ZEPATIER with a high-fat (900 kcal, 500 kcal from fat) meal to healthy subjects resulted in decreases in elbasvir AUC<sub>0-inf</sub> and C<sub>max</sub> of approximately 11% and 15%, respectively, and increases in grazoprevir AUC<sub>0-inf</sub> and C<sub>max</sub> of approximately 1.5-fold and 2.8-fold, respectively. These differences in elbasvir and grazoprevir exposure are not clinically relevant; therefore, ZEPATIER may be taken without regard to food <content styleCode="italics">[see <linkHtml href="#S2.2">Dosage and Administration (2.2)</linkHtml>]</content>.</paragraph>
                                 </text>
                                 <effectiveTime value="20160128"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="df10fc2a-409e-477d-9389-6daaf1f79fc4"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Distribution</content>
                              </paragraph>
                              <paragraph>Elbasvir and grazoprevir are extensively bound (greater than 99.9% and 98.8%, respectively) to human plasma proteins. Both elbasvir and grazoprevir bind to human serum albumin and Î±1-acid glycoprotein. Estimated apparent volume of distribution values of elbasvir and grazoprevir are approximately 680 L and 1250 L, respectively, based on population pharmacokinetic modeling. </paragraph>
                              <paragraph>In preclinical distribution studies, elbasvir distributes into most tissues including the liver; whereas grazoprevir distributes predominantly to the liver likely facilitated by the active transport through the OATP1B1/3 liver uptake transporter. </paragraph>
                           </text>
                           <effectiveTime value="20160128"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="22f4d8c1-277f-429e-bab2-69f7485c988e"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Elimination</content>
                              </paragraph>
                              <paragraph>The geometric mean apparent terminal half-life for elbasvir (50 mg) and grazoprevir (100 mg) is approximately 24 and 31 hours, respectively, in HCV-infected subjects. </paragraph>
                           </text>
                           <effectiveTime value="20160128"/>
                           <component>
                              <section>
                                 <id root="837360fd-95f5-4393-b825-91aedc2c79ea"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Metabolism</content>
                                    </paragraph>
                                    <paragraph>Elbasvir and grazoprevir are partially eliminated by oxidative metabolism, primarily by CYP3A. No circulating metabolites of either elbasvir or grazoprevir were detected in human plasma.</paragraph>
                                 </text>
                                 <effectiveTime value="20160128"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="d927daaa-8fe4-4a97-a947-bb47b983248d"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Excretion</content>
                                    </paragraph>
                                    <paragraph>The primary route of elimination of elbasvir and grazoprevir is through feces with almost all (greater than 90%) of radiolabeled dose recovered in feces compared to less than 1% in urine.</paragraph>
                                 </text>
                                 <effectiveTime value="20160128"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="158a2ec2-8d71-41f6-bdee-c093d87e0907"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Specific Populations</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20160128"/>
                           <component>
                              <section>
                                 <id root="e8c2d9d8-1e06-431a-b3f2-5c747cf9869b"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Pediatric Population</content>
                                    </paragraph>
                                    <paragraph>The pharmacokinetics of ZEPATIER in pediatric patients less than 18 years of age have not been established.</paragraph>
                                 </text>
                                 <effectiveTime value="20160128"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="975b9b58-a137-4faa-b1fd-f0d46198b9e1"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Geriatric Population</content>
                                    </paragraph>
                                    <paragraph>In population pharmacokinetic analyses, elbasvir and grazoprevir AUCs are estimated to be 16% and 45% higher, respectively, in subjects at least 65 years of age compared to subjects less than 65 years of age. </paragraph>
                                 </text>
                                 <effectiveTime value="20160128"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="47c82113-8267-4d38-8a49-c772bc8661be"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Gender</content>
                                    </paragraph>
                                    <paragraph>In population pharmacokinetic analyses, elbasvir and grazoprevir AUCs are estimated to be 50% and 30% higher, respectively, in females compared to males.</paragraph>
                                 </text>
                                 <effectiveTime value="20160128"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="709ab04a-afe8-4662-bf59-ce60267e7a23"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Weight/BMI</content>
                                    </paragraph>
                                    <paragraph>In population pharmacokinetic analyses, there was no effect of weight on elbasvir pharmacokinetics. Grazoprevir AUC is estimated to be 15% higher in a 53-kg subject compared to a 77-kg subject. This change is not clinically relevant for grazoprevir. </paragraph>
                                 </text>
                                 <effectiveTime value="20160128"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="135ff324-e02c-4893-ae10-c390b61f9018"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Race/Ethnicity</content>
                                    </paragraph>
                                    <paragraph>In population pharmacokinetic analyses, elbasvir and grazoprevir AUCs are estimated to be 15% and 50% higher, respectively, for Asians compared to Caucasians. Population pharmacokinetics estimates of exposure of elbasvir and grazoprevir were comparable between Caucasians and Black/African Americans. </paragraph>
                                 </text>
                                 <effectiveTime value="20160128"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="786aadc7-5ca1-4493-8714-e0e27989b9b4"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Renal Impairment</content>
                                    </paragraph>
                                    <paragraph>In population pharmacokinetic analyses, elbasvir AUC was 25% higher in hemodialysis-dependent subjects and 46% higher in non-dialysis-dependent subjects with severe renal impairment compared to elbasvir AUC in subjects without severe renal impairment. In population pharmacokinetic analysis in HCV-infected subjects, grazoprevir AUC was 10% higher in hemodialysis-dependent subjects and 40% higher in non-dialysis-dependent subjects with severe renal impairment compared to grazoprevir AUC in subjects without severe renal impairment. Elbasvir and grazoprevir are not removed by hemodialysis. Elbasvir and grazoprevir are unlikely to be removed by peritoneal dialysis as both are highly protein bound.</paragraph>
                                    <paragraph>Overall, changes in exposure of elbasvir and grazoprevir in HCV-infected subjects with renal impairment with or without hemodialysis are not clinically relevant <content styleCode="italics">[see <linkHtml href="#S8.8">Use in Specific Populations (8.8)</linkHtml>].</content>
                                    </paragraph>
                                 </text>
                                 <effectiveTime value="20160128"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="95577669-86ce-41a6-aaec-ea609d066474"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Hepatic Impairment</content>
                                    </paragraph>
                                    <paragraph>The pharmacokinetics of elbasvir and grazoprevir were evaluated in non-HCV-infected subjects with mild hepatic impairment (Child-Pugh Category A [CP-A], score of 5-6), moderate hepatic impairment (Child-Pugh Category B [CP-B], score of 7-9) and severe hepatic impairment (Child-Pugh Category C [CP-C], score of 10-15). In addition, the pharmacokinetics of elbasvir and grazoprevir were also evaluated in HCV-infected subjects including CP-A subjects with compensated cirrhosis.</paragraph>
                                    <paragraph>Relative to non-HCV-infected subjects with normal hepatic function, no clinically relevant differences in elbasvir AUC values were observed in non-HCV-infected subjects with mild, moderate, or severe hepatic impairment. In population pharmacokinetic analyses, elbasvir steady-state AUC was similar in HCV-infected subjects with compensated cirrhosis compared to HCV-infected, non-cirrhotic subjects.</paragraph>
                                    <paragraph>Relative to non-HCV-infected subjects with normal hepatic function, grazoprevir AUC values were higher by 1.7-fold, 5-fold, and 12-fold in non-HCV-infected subjects with mild, moderate, and severe hepatic impairment, respectively. In population pharmacokinetic analyses, grazoprevir steady-state AUC values were higher by 1.65-fold in HCV-infected subjects with compensated cirrhosis compared to HCV-infected, non-cirrhotic subjects. </paragraph>
                                 </text>
                                 <effectiveTime value="20160128"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="b2269790-d316-416a-8aba-cd06e9b126cd"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Drug Interaction Studies </content>
                              </paragraph>
                              <paragraph>Drug interaction studies were performed in healthy adults with elbasvir, grazoprevir, or co-administered elbasvir and grazoprevir and drugs likely to be co-administered or drugs commonly used as probes for pharmacokinetic interactions. <linkHtml href="#t8">Table 8</linkHtml> summarizes the effects of co-administered drugs on the exposures of the individual components of ZEPATIER (elbasvir and grazoprevir). <linkHtml href="#t9">Table 9</linkHtml> summarizes the effects of the individual components of ZEPATIER on the exposures of the co-administered drugs. For information regarding clinical recommendations, <content styleCode="italics">[see <linkHtml href="#S4">Contraindications (4)</linkHtml>, <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>
                                    <linkHtml/>, and <linkHtml href="#S7">Drug Interactions (7)</linkHtml>].</content>
                              </paragraph>
                              <paragraph>Elbasvir and grazoprevir are substrates of CYP3A and P-gp, but the role of intestinal P-gp in the absorption of elbasvir and grazoprevir appears to be minimal. Co-administration of moderate and strong CYP3A inducers with ZEPATIER may decrease elbasvir and grazoprevir plasma concentrations, leading to reduced therapeutic effect of ZEPATIER. Co-administration of strong CYP3A4 inhibitors with ZEPATIER may increase elbasvir and grazoprevir plasma concentrations.</paragraph>
                              <paragraph>Grazoprevir is a substrate of OATP1B1/3. Co-administration of ZEPATIER with drugs that inhibit OATP1B1/3 transporters may result in a clinically relevant increase in grazoprevir plasma concentrations. </paragraph>
                              <paragraph>Elbasvir is not a CYP3A inhibitor <content styleCode="italics">in vitro</content> and grazoprevir is a weak CYP3A inhibitor in humans. Co-administration with grazoprevir resulted in a 34% increase in plasma exposure of midazolam and a 43% increase in plasma exposure of tacrolimus (see <linkHtml href="#t6">Tables 6</linkHtml> and <linkHtml href="#t9">9</linkHtml>). Elbasvir inhibited P-gp <content styleCode="italics">in vitro</content>, but no clinically relevant increases in concentrations of digoxin (a P-gp substrate; see <linkHtml href="#t9">Table 9</linkHtml>) were observed by co-administration of elbasvir. Grazoprevir is not a P-gp inhibitor <content styleCode="italics">in vitro</content>. Elbasvir and grazoprevir are inhibitors of the drug transporter breast cancer resistance protein (BCRP) at the intestinal level in humans and may increase plasma concentrations of co-administered BCRP substrates. </paragraph>
                              <paragraph>Clinically significant drug interactions with ZEPATIER as an inhibitor of other CYP enzymes (CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, and CYP2D6), UGT1A1, and esterases (CES1, CES2, and CatA), are not expected, and multiple-dose administration of elbasvir or grazoprevir is unlikely to induce the metabolism of drugs metabolized by CYP1A2, CYP2B6, or CYP3A based on <content styleCode="italics">in vitro</content> data. </paragraph>
                              <table width="100%" ID="t8">
                                 <caption>Table 8: Drug Interactions: Changes in Pharmacokinetics of Elbasvir or Grazoprevir in the Presence of Co-Administered Drug</caption>
                                 <col width="11%" align="center" valign="middle"/>
                                 <col width="12%" align="center" valign="middle"/>
                                 <col width="13%" align="center" valign="middle"/>
                                 <col width="7%" align="center" valign="middle"/>
                                 <col width="12%" align="center" valign="middle"/>
                                 <col width="15%" align="center" valign="middle"/>
                                 <col width="15%" align="center" valign="middle"/>
                                 <col width="15%" align="center" valign="middle"/>
                                 <thead>
                                    <tr styleCode="Botrule">
                                       <th styleCode="Lrule Rrule" rowspan="2">Co-Administered Drug</th>
                                       <th styleCode="Rrule" rowspan="2">Regimen of Co-Administered Drug</th>
                                       <th styleCode="Rrule" rowspan="2">Regimen of EBR or/and GZR</th>
                                       <th styleCode="Rrule" rowspan="2">N</th>
                                       <th styleCode="Rrule" colspan="4">Geometric Mean Ratio [90% CI] of EBR and GZR PK with/without Co-Administered Drug (No Effect=1.00)</th>
                                    </tr>
                                    <tr>
                                       <th styleCode="Rrule"/>
                                       <th styleCode="Rrule">AUC<footnote ID="t8f1">AUC<sub>0-inf</sub> for single-dose, AUC<sub>0-24</sub> for once daily.</footnote>
                                       </th>
                                       <th styleCode="Rrule">C<sub>max</sub>
                                       </th>
                                       <th styleCode="Rrule">C24</th>
                                    </tr>
                                 </thead>
                                 <tfoot>
                                    <tr>
                                       <td align="left" valign="top" colspan="8">Abbreviations: EBR, elbasvir; GZR, grazoprevir; IV, intravenous; PO, oral; EBR + GZR, administration of EBR and GZR as separate pills; EBR/GZR, administration of EBR and GZR as a single fixed-dose combination tablet.</td>
                                    </tr>
                                 </tfoot>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" colspan="8">Antifungal</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" rowspan="2">Ketoconazole</td>
                                       <td styleCode="Rrule">400 mg once daily</td>
                                       <td styleCode="Rrule">EBR 50 mg single-dose</td>
                                       <td styleCode="Rrule">7</td>
                                       <td styleCode="Rrule">EBR</td>
                                       <td styleCode="Rrule">1.80 (1.41, 2.29)</td>
                                       <td styleCode="Rrule">1.29 (1.00, 1.66)</td>
                                       <td styleCode="Rrule">1.89 (1.37, 2.60)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Rrule">400 mg once daily</td>
                                       <td styleCode="Rrule">GZR 100 mg single-dose</td>
                                       <td styleCode="Rrule">8</td>
                                       <td styleCode="Rrule">GZR</td>
                                       <td styleCode="Rrule">3.02 (2.42, 3.76)</td>
                                       <td styleCode="Rrule">1.13 (0.77, 1.67)</td>
                                       <td styleCode="Rrule">2.01 (1.49, 2.71)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" colspan="8">Antimycobacterial</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" rowspan="5">Rifampin</td>
                                       <td styleCode="Rrule">600 mg single-dose IV</td>
                                       <td styleCode="Rrule">EBR 50 mg single-dose</td>
                                       <td styleCode="Rrule">14</td>
                                       <td styleCode="Rrule">EBR</td>
                                       <td styleCode="Rrule">1.22 (1.06, 1.40)</td>
                                       <td styleCode="Rrule">1.41 (1.18, 1.68)</td>
                                       <td styleCode="Rrule">1.31 (1.12, 1.53)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Rrule">600 mg single-dose PO</td>
                                       <td styleCode="Rrule">EBR 50 mg single-dose</td>
                                       <td styleCode="Rrule">14</td>
                                       <td styleCode="Rrule">EBR</td>
                                       <td styleCode="Rrule">1.17 (0.98, 1.39)</td>
                                       <td styleCode="Rrule">1.29 (1.06, 1.58)</td>
                                       <td styleCode="Rrule">1.21 (1.03, 1.43)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Rrule">600 mg PO once daily</td>
                                       <td styleCode="Rrule">GZR 200 mg once daily</td>
                                       <td styleCode="Rrule">12</td>
                                       <td styleCode="Rrule">GZR</td>
                                       <td styleCode="Rrule">0.93 (0.75, 1.17)</td>
                                       <td styleCode="Rrule">1.16 (0.82, 1.65)</td>
                                       <td styleCode="Rrule">0.10 (0.07, 0.13)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Rrule">600 mg IV single-dose</td>
                                       <td styleCode="Rrule">GZR 200 mg single-dose</td>
                                       <td styleCode="Rrule">12</td>
                                       <td styleCode="Rrule">GZR</td>
                                       <td styleCode="Rrule">10.21 (8.68, 12.00)</td>
                                       <td styleCode="Rrule">10.94 (8.92, 13.43)</td>
                                       <td styleCode="Rrule">1.77 (1.40, 2.24)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Rrule">600 mg PO single-dose</td>
                                       <td styleCode="Rrule">GZR 200 mg once daily</td>
                                       <td styleCode="Rrule">12</td>
                                       <td styleCode="Rrule">GZR</td>
                                       <td styleCode="Rrule">8.35 (7.38, 9.45)<footnote ID="t8f2">AUC<sub>0-24</sub>
                                          </footnote>
                                       </td>
                                       <td styleCode="Rrule">6.52 (5.16, 8.24)</td>
                                       <td styleCode="Rrule">1.62 (1.32, 1.98)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" colspan="8">HCV Antiviral</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">EBR</td>
                                       <td styleCode="Rrule">20 mg once daily</td>
                                       <td styleCode="Rrule">GZR 200 mg once daily</td>
                                       <td styleCode="Rrule">10</td>
                                       <td styleCode="Rrule">GZR</td>
                                       <td styleCode="Rrule">0.90 (0.63, 1.28)</td>
                                       <td styleCode="Rrule">0.87 (0.50, 1.52)</td>
                                       <td styleCode="Rrule">0.94 (0.77, 1.15)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">GZR</td>
                                       <td styleCode="Rrule">200 mg once daily</td>
                                       <td styleCode="Rrule">EBR 20 mg once daily</td>
                                       <td styleCode="Rrule">10</td>
                                       <td styleCode="Rrule">EBR</td>
                                       <td styleCode="Rrule">1.01 (0.83, 1.24)</td>
                                       <td styleCode="Rrule">0.93 (0.76, 1.13)</td>
                                       <td styleCode="Rrule">1.02 (0.83, 1.24)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" colspan="8">HIV Protease Inhibitor</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" rowspan="2">Atazanavir/ ritonavir</td>
                                       <td styleCode="Rrule">300 mg/100 mg once daily</td>
                                       <td styleCode="Rrule">EBR 50 mg once daily</td>
                                       <td styleCode="Rrule">10</td>
                                       <td styleCode="Rrule">EBR</td>
                                       <td styleCode="Rrule">4.76 (4.07, 5.56)</td>
                                       <td styleCode="Rrule">4.15 (3.46, 4.97)</td>
                                       <td styleCode="Rrule">6.45 (5.51, 7.54)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Rrule">300 mg/100 mg once daily</td>
                                       <td styleCode="Rrule">GZR 200 mg once daily</td>
                                       <td styleCode="Rrule">12</td>
                                       <td styleCode="Rrule">GZR</td>
                                       <td styleCode="Rrule">10.58 (7.78, 14.39)</td>
                                       <td styleCode="Rrule">6.24 (4.42, 8.81)</td>
                                       <td styleCode="Rrule">11.64 (7.96, 17.02)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" rowspan="2">Darunavir/ ritonavir</td>
                                       <td styleCode="Rrule">600 mg/100 mg twice daily</td>
                                       <td styleCode="Rrule">EBR 50 mg once daily</td>
                                       <td styleCode="Rrule">10</td>
                                       <td styleCode="Rrule">EBR</td>
                                       <td styleCode="Rrule">1.66 (1.35, 2.05)</td>
                                       <td styleCode="Rrule">1.67 (1.36, 2.05)</td>
                                       <td styleCode="Rrule">1.82 (1.39, 2.39)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Rrule">600 mg/100 mg twice daily</td>
                                       <td styleCode="Rrule">GZR 200 mg once daily</td>
                                       <td styleCode="Rrule">13</td>
                                       <td styleCode="Rrule">GZR</td>
                                       <td styleCode="Rrule">7.50 (5.92, 9.51)</td>
                                       <td styleCode="Rrule">5.27 (4.04, 6.86)</td>
                                       <td styleCode="Rrule">8.05 (6.33, 10.24)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" rowspan="2">Lopinavir/ ritonavir</td>
                                       <td styleCode="Rrule">400 mg/100 mg twice daily</td>
                                       <td styleCode="Rrule">EBR 50 mg once daily</td>
                                       <td styleCode="Rrule">10</td>
                                       <td styleCode="Rrule">EBR</td>
                                       <td styleCode="Rrule">3.71 (3.05, 4.53)</td>
                                       <td styleCode="Rrule">2.87 (2.29, 3.58)</td>
                                       <td styleCode="Rrule">4.58 (3.72, 5.64)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Rrule">400 mg/100 mg twice daily</td>
                                       <td styleCode="Rrule">GZR 200 mg once daily</td>
                                       <td styleCode="Rrule">13</td>
                                       <td styleCode="Rrule">GZR</td>
                                       <td styleCode="Rrule">12.86 (10.25, 16.13)</td>
                                       <td styleCode="Rrule">7.31 (5.65, 9.45)</td>
                                       <td styleCode="Rrule">21.70 (12.99, 36.25)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Ritonavir<footnote ID="t83">Higher doses of ritonavir have not been tested in a drug interaction study with GZR.</footnote>
                                       </td>
                                       <td styleCode="Rrule">100 mg twice daily</td>
                                       <td styleCode="Rrule">GZR 200 mg single-dose</td>
                                       <td styleCode="Rrule">10</td>
                                       <td styleCode="Rrule">GZR</td>
                                       <td styleCode="Rrule">2.03 (1.60, 2.56)</td>
                                       <td styleCode="Rrule">1.15 (0.60, 2.18)</td>
                                       <td styleCode="Rrule">1.88 (1.65, 2.14)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" colspan="8">HIV Integrase Strand Transfer Inhibitor</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" rowspan="2">Dolutegravir</td>
                                       <td styleCode="Rrule">50 mg single-dose</td>
                                       <td styleCode="Rrule">EBR 50 mg + GZR 200 mg once daily</td>
                                       <td styleCode="Rrule">12</td>
                                       <td styleCode="Rrule">EBR</td>
                                       <td styleCode="Rrule">0.98 (0.93, 1.04)</td>
                                       <td styleCode="Rrule">0.97 (0.89, 1.05)</td>
                                       <td styleCode="Rrule">0.98 (0.93, 1.03)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Rrule">50 mg single-dose</td>
                                       <td styleCode="Rrule">EBR 50 mg + GZR 200 mg once daily</td>
                                       <td styleCode="Rrule">12</td>
                                       <td styleCode="Rrule">GZR</td>
                                       <td styleCode="Rrule">0.81 (0.67, 0.97)</td>
                                       <td styleCode="Rrule">0.64 (0.44, 0.93)</td>
                                       <td styleCode="Rrule">0.86 (0.79, 0.93)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" rowspan="2">Raltegravir</td>
                                       <td styleCode="Rrule">400 mg single-dose</td>
                                       <td styleCode="Rrule">EBR 50 mg single-dose</td>
                                       <td styleCode="Rrule">10</td>
                                       <td styleCode="Rrule">EBR</td>
                                       <td styleCode="Rrule">0.81 (0.57, 1.17)</td>
                                       <td styleCode="Rrule">0.89 (0.61, 1.29)</td>
                                       <td styleCode="Rrule">0.80 (0.55, 1.16)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Rrule">400 mg twice daily</td>
                                       <td styleCode="Rrule">GZR 200 mg once daily</td>
                                       <td styleCode="Rrule">11</td>
                                       <td styleCode="Rrule">GZR</td>
                                       <td styleCode="Rrule">0.89 (0.72, 1.09)</td>
                                       <td styleCode="Rrule">0.85 (0.62, 1.16)</td>
                                       <td styleCode="Rrule">0.90 (0.82, 0.99)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" colspan="8">HIV Non-Nucleoside Reverse Transcriptase Inhibitor</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" rowspan="2">Efavirenz</td>
                                       <td styleCode="Rrule">600 mg once daily</td>
                                       <td styleCode="Rrule">EBR 50 mg once daily</td>
                                       <td styleCode="Rrule">10</td>
                                       <td styleCode="Rrule">EBR</td>
                                       <td styleCode="Rrule">0.46 (0.36, 0.59)</td>
                                       <td styleCode="Rrule">0.55 (0.41, 0.73)</td>
                                       <td styleCode="Rrule">0.41 (0.28, 0.59)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Rrule">600 mg once daily</td>
                                       <td styleCode="Rrule">GZR 200 mg once daily</td>
                                       <td styleCode="Rrule">12</td>
                                       <td styleCode="Rrule">GZR</td>
                                       <td styleCode="Rrule">0.17 (0.13, 0.24)</td>
                                       <td styleCode="Rrule">0.13 (0.09, 0.19)</td>
                                       <td styleCode="Rrule">0.31 (0.25, 0.38)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" rowspan="2">Rilpivirine</td>
                                       <td styleCode="Rrule">25 mg once daily</td>
                                       <td styleCode="Rrule">EBR 50 mg + GZR 200 mg once daily</td>
                                       <td styleCode="Rrule">19</td>
                                       <td styleCode="Rrule">EBR</td>
                                       <td styleCode="Rrule">1.07 (1.00, 1.15)</td>
                                       <td styleCode="Rrule">1.07 (0.99, 1.16)</td>
                                       <td styleCode="Rrule">1.04 (0.98, 1.11)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Rrule">25 mg once daily</td>
                                       <td styleCode="Rrule">EBR 50 mg + GZR 200 mg once daily</td>
                                       <td styleCode="Rrule">19</td>
                                       <td styleCode="Rrule">GZR</td>
                                       <td styleCode="Rrule">0.98 (0.89, 1.07)</td>
                                       <td styleCode="Rrule">0.97 (0.83, 1.14)</td>
                                       <td styleCode="Rrule">1.00 (0.93, 1.07)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" colspan="8">HIV Nucleotide Reverse Transcriptase Inhibitor</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" rowspan="2">Tenofovir disoproxil fumarate</td>
                                       <td styleCode="Rrule">300 mg once daily</td>
                                       <td styleCode="Rrule">EBR 50 mg once daily</td>
                                       <td styleCode="Rrule">10</td>
                                       <td styleCode="Rrule">EBR</td>
                                       <td styleCode="Rrule">0.93 (0.82, 1.05)</td>
                                       <td styleCode="Rrule">0.88 (0.77, 1.00)</td>
                                       <td styleCode="Rrule">0.92 (0.81, 1.05)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Rrule">300 mg once daily</td>
                                       <td styleCode="Rrule">GZR 200 mg once daily</td>
                                       <td styleCode="Rrule">12</td>
                                       <td styleCode="Rrule">GZR</td>
                                       <td styleCode="Rrule">0.86 (0.65, 1.12)</td>
                                       <td styleCode="Rrule">0.78 (0.51, 1.18)</td>
                                       <td styleCode="Rrule">0.89 (0.78, 1.01)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" colspan="8">Immunosuppressant</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" rowspan="2">Cyclosporine</td>
                                       <td styleCode="Rrule">400 mg single-dose</td>
                                       <td styleCode="Rrule">EBR 50 mg + GZR 200 mg once daily</td>
                                       <td styleCode="Rrule">14</td>
                                       <td styleCode="Rrule">EBR</td>
                                       <td styleCode="Rrule">1.98 (1.84, 2.13)</td>
                                       <td styleCode="Rrule">1.95 (1.84, 2.07)</td>
                                       <td styleCode="Rrule">2.21 (1.98, 2.47)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Rrule">400 mg single-dose</td>
                                       <td styleCode="Rrule">EBR 50 mg + GZR 200 mg once daily</td>
                                       <td styleCode="Rrule">14</td>
                                       <td styleCode="Rrule">GZR</td>
                                       <td styleCode="Rrule">15.21 (12.83, 18.04)</td>
                                       <td styleCode="Rrule">17.00 (12.94, 22.34)</td>
                                       <td styleCode="Rrule">3.39 (2.82, 4.09)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" rowspan="2">Mycophenolate mofetil</td>
                                       <td styleCode="Rrule">1000 mg single-dose</td>
                                       <td styleCode="Rrule">EBR 50 mg + GZR 200 mg once daily</td>
                                       <td styleCode="Rrule">14</td>
                                       <td styleCode="Rrule">EBR</td>
                                       <td styleCode="Rrule">1.07 (1.00, 1.14)</td>
                                       <td styleCode="Rrule">1.07 (0.98, 1.16)</td>
                                       <td styleCode="Rrule">1.05 (0.97, 1.14)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Rrule">1000 mg single-dose</td>
                                       <td styleCode="Rrule">EBR 50 mg + GZR 200 mg once daily</td>
                                       <td styleCode="Rrule">14</td>
                                       <td styleCode="Rrule">GZR</td>
                                       <td styleCode="Rrule">0.74 (0.60, 0.92)</td>
                                       <td styleCode="Rrule">0.58 (0.42, 0.82)</td>
                                       <td styleCode="Rrule">0.97 (0.89, 1.06)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" rowspan="2">Prednisone</td>
                                       <td styleCode="Rrule">40 mg single-dose</td>
                                       <td styleCode="Rrule">EBR 50 mg + GZR 200 mg once daily</td>
                                       <td styleCode="Rrule">14</td>
                                       <td styleCode="Rrule">EBR</td>
                                       <td styleCode="Rrule">1.17 (1.11, 1.24)</td>
                                       <td styleCode="Rrule">1.25 (1.16, 1.35)</td>
                                       <td styleCode="Rrule">1.04 (0.97, 1.12)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Rrule">40 mg single-dose</td>
                                       <td styleCode="Rrule">EBR 50 mg + GZR 200 mg once daily</td>
                                       <td styleCode="Rrule">14</td>
                                       <td styleCode="Rrule">GZR</td>
                                       <td styleCode="Rrule">1.09 (0.95, 1.25)</td>
                                       <td styleCode="Rrule">1.34 (1.10, 1.62)</td>
                                       <td styleCode="Rrule">0.93 (0.87, 1.00)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" rowspan="2">Tacrolimus</td>
                                       <td styleCode="Rrule">2 mg single-dose</td>
                                       <td styleCode="Rrule">EBR 50 mg + GZR 200 mg once daily</td>
                                       <td styleCode="Rrule">16</td>
                                       <td styleCode="Rrule">EBR</td>
                                       <td styleCode="Rrule">0.97 (0.90, 1.06)</td>
                                       <td styleCode="Rrule">0.99 (0.88, 1.10)</td>
                                       <td styleCode="Rrule">0.92 (0.83, 1.02)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Rrule">2 mg single-dose</td>
                                       <td styleCode="Rrule">EBR 50 mg + GZR 200 mg once daily</td>
                                       <td styleCode="Rrule">16</td>
                                       <td styleCode="Rrule">GZR</td>
                                       <td styleCode="Rrule">1.12 (0.97, 1.30)</td>
                                       <td styleCode="Rrule">1.07 (0.83, 1.37)</td>
                                       <td styleCode="Rrule">0.94 (0.87, 1.02)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" colspan="8">Opioid-Substitution Therapy</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Buprenorphine/naloxone</td>
                                       <td styleCode="Rrule">8 mg/2 mg single-dose</td>
                                       <td styleCode="Rrule">EBR 50 mg single-dose</td>
                                       <td styleCode="Rrule">15</td>
                                       <td styleCode="Rrule">EBR</td>
                                       <td styleCode="Rrule">1.22 (0.98, 1.52)</td>
                                       <td styleCode="Rrule">1.13 (0.87, 1.46)</td>
                                       <td styleCode="Rrule">1.22 (0.99, 1.51)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" colspan="8">Acid-Reducing Agent</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" rowspan="2">Famotidine</td>
                                       <td styleCode="Rrule">20 mg single-dose</td>
                                       <td styleCode="Rrule">EBR 50 mg/ GZR 100 mg single-dose</td>
                                       <td styleCode="Rrule">16</td>
                                       <td styleCode="Rrule">EBR</td>
                                       <td styleCode="Rrule">1.05 (0.92, 1.18)</td>
                                       <td styleCode="Rrule">1.11 (0.98, 1.26)</td>
                                       <td styleCode="Rrule">1.03 (0.91, 1.17)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Rrule">20 mg single-dose</td>
                                       <td styleCode="Rrule">EBR 50 mg/ GZR 100 mg single-dose</td>
                                       <td styleCode="Rrule">16</td>
                                       <td styleCode="Rrule">GZR</td>
                                       <td styleCode="Rrule">1.10 (0.95, 1.28)</td>
                                       <td styleCode="Rrule">0.89 (0.71, 1.11)</td>
                                       <td styleCode="Rrule">1.12 (0.97, 1.30)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" rowspan="2">Pantoprazole</td>
                                       <td styleCode="Rrule">40 mg once daily</td>
                                       <td styleCode="Rrule">EBR 50 mg/ GZR 100 mg single-dose</td>
                                       <td styleCode="Rrule">16</td>
                                       <td styleCode="Rrule">EBR</td>
                                       <td styleCode="Rrule">1.05 (0.93, 1.18)</td>
                                       <td styleCode="Rrule">1.02 (0.92, 1.14)</td>
                                       <td styleCode="Rrule">1.03 (0.92, 1.17)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Rrule">40 mg once daily</td>
                                       <td styleCode="Rrule">EBR 50 mg/ GZR 100 mg single-dose</td>
                                       <td styleCode="Rrule">16</td>
                                       <td styleCode="Rrule">GZR</td>
                                       <td styleCode="Rrule">1.12 (0.96, 1.30)</td>
                                       <td styleCode="Rrule">1.10 (0.89, 1.37)</td>
                                       <td styleCode="Rrule">1.17 (1.02, 1.34)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" colspan="8">Phosphate Binder</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" rowspan="2">Calcium acetate</td>
                                       <td styleCode="Rrule">2668 mg single-dose</td>
                                       <td styleCode="Rrule">EBR 50 mg + GZR 100 mg single-dose</td>
                                       <td styleCode="Rrule">12</td>
                                       <td styleCode="Rrule">EBR</td>
                                       <td styleCode="Rrule">0.92 (0.75, 1.14)</td>
                                       <td styleCode="Rrule">0.86 (0.71, 1.04)</td>
                                       <td styleCode="Rrule">0.87 (0.70, 1.09)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Rrule">2668 mg single-dose</td>
                                       <td styleCode="Rrule">EBR 50 mg + GZR 100 mg single-dose</td>
                                       <td styleCode="Rrule">12</td>
                                       <td styleCode="Rrule">GZR</td>
                                       <td styleCode="Rrule">0.79 (0.68, 0.91)</td>
                                       <td styleCode="Rrule">0.57 (0.40, 0.83)</td>
                                       <td styleCode="Rrule">0.77 (0.61, 0.99)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" rowspan="2">Sevelamer carbonate</td>
                                       <td styleCode="Rrule">2400 mg single-dose</td>
                                       <td styleCode="Rrule">EBR 50 mg + GZR 100 mg single-dose</td>
                                       <td styleCode="Rrule">12</td>
                                       <td styleCode="Rrule">EBR</td>
                                       <td styleCode="Rrule">1.13 (0.94, 1.37)</td>
                                       <td styleCode="Rrule">1.07 (0.88, 1.29)</td>
                                       <td styleCode="Rrule">1.22 (1.02, 1.45)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Rrule">2400 mg single-dose</td>
                                       <td styleCode="Rrule">EBR 50 mg + GZR 100 mg single-dose</td>
                                       <td styleCode="Rrule">12</td>
                                       <td styleCode="Rrule">GZR</td>
                                       <td styleCode="Rrule">0.82 (0.68, 0.99)</td>
                                       <td styleCode="Rrule">0.53 (0.37, 0.76)</td>
                                       <td styleCode="Rrule">0.84 (0.71, 0.99)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" colspan="8">Statin</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Atorvastatin</td>
                                       <td styleCode="Rrule">20 mg single-dose</td>
                                       <td styleCode="Rrule">GZR 200 mg once daily</td>
                                       <td styleCode="Rrule">9</td>
                                       <td styleCode="Rrule">GZR</td>
                                       <td styleCode="Rrule">1.26 (0.97, 1.64)</td>
                                       <td styleCode="Rrule">1.26 (0.83, 1.90)</td>
                                       <td styleCode="Rrule">1.11 (1.00, 1.23)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Pitavastatin</td>
                                       <td styleCode="Rrule">1 mg single-dose</td>
                                       <td styleCode="Rrule">GZR 200 mg once daily</td>
                                       <td styleCode="Rrule">9</td>
                                       <td styleCode="Rrule">GZR</td>
                                       <td styleCode="Rrule">0.81 (0.70, 0.95)</td>
                                       <td styleCode="Rrule">0.72 (0.57, 0.92)</td>
                                       <td styleCode="Rrule">0.91 (0.82, 1.01)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" rowspan="2">Pravastatin</td>
                                       <td styleCode="Rrule">40 mg single-dose</td>
                                       <td styleCode="Rrule">EBR 50 mg + GZR 200 mg once daily</td>
                                       <td styleCode="Rrule">12</td>
                                       <td styleCode="Rrule">EBR</td>
                                       <td styleCode="Rrule">0.98 (0.93, 1.02)</td>
                                       <td styleCode="Rrule">0.97 (0.89, 1.05)</td>
                                       <td styleCode="Rrule">0.97 (0.92, 1.02)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Rrule">40 mg single-dose</td>
                                       <td styleCode="Rrule">EBR 50 mg + GZR 200 mg once daily</td>
                                       <td styleCode="Rrule">12</td>
                                       <td styleCode="Rrule">GZR</td>
                                       <td styleCode="Rrule">1.24 (1.00, 1.53)</td>
                                       <td styleCode="Rrule">1.42 (1.00, 2.03)</td>
                                       <td styleCode="Rrule">1.07 (0.99, 1.16)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" rowspan="3">Rosuvastatin</td>
                                       <td styleCode="Rrule">10 mg single-dose</td>
                                       <td styleCode="Rrule">EBR 50 mg + GZR 200 mg single-dose</td>
                                       <td styleCode="Rrule">11</td>
                                       <td styleCode="Rrule">EBR</td>
                                       <td styleCode="Rrule">1.09 (0.98, 1.21)</td>
                                       <td styleCode="Rrule">1.11 (0.99, 1.26)</td>
                                       <td styleCode="Rrule">0.96 (0.86, 1.08)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Rrule">10 mg single-dose</td>
                                       <td styleCode="Rrule">GZR 200 mg once daily</td>
                                       <td styleCode="Rrule">11</td>
                                       <td styleCode="Rrule">GZR</td>
                                       <td styleCode="Rrule">1.16 (0.94, 1.44)</td>
                                       <td styleCode="Rrule">1.13 (0.77, 1.65)</td>
                                       <td styleCode="Rrule">0.93 (0.84, 1.03)</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Rrule">10 mg single-dose</td>
                                       <td styleCode="Rrule">EBR 50 mg + GZR 200 mg once daily</td>
                                       <td styleCode="Rrule">11</td>
                                       <td styleCode="Rrule">GZR</td>
                                       <td styleCode="Rrule">1.01 (0.79, 1.28)</td>
                                       <td styleCode="Rrule">0.97 (0.63, 1.50)</td>
                                       <td styleCode="Rrule">0.95 (0.87, 1.04)</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <table width="100%" ID="t9">
                                 <caption>Table 9: Drug Interactions: Changes in Pharmacokinetics for Co-Administered Drug in the Presence of Elbasvir, Grazoprevir, or Co-Administered Elbasvir and Grazoprevir</caption>
                                 <col width="15%" align="center" valign="middle"/>
                                 <col width="15%" align="center" valign="middle"/>
                                 <col width="15%" align="center" valign="middle"/>
                                 <col width="20%" align="center" valign="middle"/>
                                 <col width="5%" align="center" valign="middle"/>
                                 <col width="10%" align="center" valign="middle"/>
                                 <col width="10%" align="center" valign="middle"/>
                                 <col width="10%" align="center" valign="middle"/>
                                 <thead>
                                    <tr styleCode="Botrule">
                                       <th styleCode="Lrule Rrule" rowspan="2">Co-Administered Drug</th>
                                       <th styleCode="Rrule" rowspan="2">Regimen of Co-Administered Drug</th>
                                       <th styleCode="Rrule" rowspan="2">EBR or/and GZR Administration</th>
                                       <th styleCode="Rrule" rowspan="2">EBR or/and GZR Regimen</th>
                                       <th styleCode="Rrule" rowspan="2">N</th>
                                       <th styleCode="Rrule" colspan="3">Geometric Mean Ratio [90% CI] of Co-Administered Drug PK with/without EBR or/and GZR (No Effect=1.00)</th>
                                    </tr>
                                    <tr>
                                       <th styleCode="Rrule">AUC<footnote ID="t9f1">AUC<sub>0-inf</sub> for single-dose administration; AUC<sub>0-24</sub> for once daily administration; AUC<sub>0-12</sub> for twice daily administration</footnote>
                                       </th>
                                       <th styleCode="Rrule">C<sub>max</sub>
                                       </th>
                                       <th styleCode="Rrule">C<sub>trough</sub>
                                          <footnote ID="t9f2">C24 for once daily administration; C12 for twice daily administration.</footnote>
                                       </th>
                                    </tr>
                                 </thead>
                                 <tfoot>
                                    <tr>
                                       <td align="left" valign="top" colspan="8">Abbreviations: EBR, elbasvir; GZR, grazoprevir; EBR + GZR, administration of EBR and GZR as separate tablets</td>
                                    </tr>
                                 </tfoot>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" colspan="8">P-gp Substrate</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Digoxin</td>
                                       <td styleCode="Rrule">Digoxin 0.25 mg single-dose</td>
                                       <td styleCode="Rrule">EBR</td>
                                       <td styleCode="Rrule">50 mg once daily</td>
                                       <td styleCode="Rrule">18</td>
                                       <td styleCode="Rrule">1.11 (1.02, 1.22)</td>
                                       <td styleCode="Rrule">1.47 (1.25, 1.73)</td>
                                       <td styleCode="Rrule">--</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" colspan="8">CYP3A Substrate</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Midazolam</td>
                                       <td styleCode="Rrule">Midazolam 2 mg single-dose</td>
                                       <td styleCode="Rrule">GZR</td>
                                       <td styleCode="Rrule">200 mg once daily</td>
                                       <td styleCode="Rrule">11</td>
                                       <td styleCode="Rrule">1.34 (1.29, 1.39)</td>
                                       <td styleCode="Rrule">1.15 (1.01, 1.31)</td>
                                       <td styleCode="Rrule">--</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" colspan="8">CYP2C8 Substrate</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Montelukast</td>
                                       <td styleCode="Rrule">Montelukast 10 mg single-dose</td>
                                       <td styleCode="Rrule">GZR</td>
                                       <td styleCode="Rrule">200 mg once daily</td>
                                       <td styleCode="Rrule">23</td>
                                       <td styleCode="Rrule">1.11 (1.01, 1.20)</td>
                                       <td styleCode="Rrule">0.92 (0.81, 1.06)</td>
                                       <td styleCode="Rrule">1.39 (1.25, 1.56)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" colspan="8">HCV Antiviral</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">GS-331007</td>
                                       <td styleCode="Rrule">Sofosbuvir 400 mg single-dose</td>
                                       <td styleCode="Rrule">EBR + GZR </td>
                                       <td styleCode="Rrule">50 mg + 200 mg once daily</td>
                                       <td styleCode="Rrule">16</td>
                                       <td styleCode="Rrule">1.13 (1.05, 1.21)</td>
                                       <td styleCode="Rrule">0.87 (0.78, 0.96)</td>
                                       <td styleCode="Rrule">1.53 (1.43, 1.63)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Sofosbuvir</td>
                                       <td styleCode="Rrule">Sofosbuvir 400 mg single-dose</td>
                                       <td styleCode="Rrule">EBR + GZR </td>
                                       <td styleCode="Rrule">50 mg + 200 mg once daily</td>
                                       <td styleCode="Rrule">16</td>
                                       <td styleCode="Rrule">2.43 (2.12, 2.79)<footnote ID="t9f3">N=14</footnote>
                                       </td>
                                       <td styleCode="Rrule">2.27 (1.72, 2.99)</td>
                                       <td styleCode="Rrule">--</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" colspan="8">HIV Protease Inhibitor</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" rowspan="2">Atazanavir/ ritonavir</td>
                                       <td styleCode="Rrule">Atazanavir 300 mg/ ritonavir 100 mg once daily</td>
                                       <td styleCode="Rrule">EBR</td>
                                       <td styleCode="Rrule">50 mg once daily</td>
                                       <td styleCode="Rrule">8</td>
                                       <td styleCode="Rrule">1.07 (0.98, 1.17)</td>
                                       <td styleCode="Rrule">1.02 (0.96, 1.08)</td>
                                       <td styleCode="Rrule">1.15 (1.02, 1.29)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Rrule">Atazanavir 300 mg/ ritonavir 100 mg once daily</td>
                                       <td styleCode="Rrule">GZR</td>
                                       <td styleCode="Rrule">200 mg once daily</td>
                                       <td styleCode="Rrule">11</td>
                                       <td styleCode="Rrule">1.43 (1.30, 1.57)</td>
                                       <td styleCode="Rrule">1.12 (1.01, 1.24)</td>
                                       <td styleCode="Rrule">1.23 (1.13, 1.34)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" rowspan="2">Darunavir/ ritonavir</td>
                                       <td styleCode="Rrule">Darunavir 600 mg/ ritonavir 100 mg twice daily</td>
                                       <td styleCode="Rrule">EBR</td>
                                       <td styleCode="Rrule">50 mg once daily</td>
                                       <td styleCode="Rrule">8</td>
                                       <td styleCode="Rrule">0.95 (0.86, 1.06)</td>
                                       <td styleCode="Rrule">0.95 (0.85, 1.05)</td>
                                       <td styleCode="Rrule">0.94 (0.85, 1.05)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Rrule">Darunavir 600 mg/ ritonavir 100 mg twice daily</td>
                                       <td styleCode="Rrule">GZR</td>
                                       <td styleCode="Rrule">200 mg once daily</td>
                                       <td styleCode="Rrule">13</td>
                                       <td styleCode="Rrule">1.11 (0.99, 1.24)</td>
                                       <td styleCode="Rrule">1.10 (0.96, 1.25)</td>
                                       <td styleCode="Rrule">1.00 (0.85, 1.18)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" rowspan="2">Lopinavir/ ritonavir</td>
                                       <td styleCode="Rrule">Lopinavir 400 mg/ ritonavir 100 mg twice daily</td>
                                       <td styleCode="Rrule">EBR</td>
                                       <td styleCode="Rrule">50 mg once daily</td>
                                       <td styleCode="Rrule">9</td>
                                       <td styleCode="Rrule">1.02 (0.93, 1.13)</td>
                                       <td styleCode="Rrule">1.02 (0.92, 1.13)</td>
                                       <td styleCode="Rrule">1.07 (0.97, 1.18)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Rrule">Lopinavir 400 mg/ ritonavir 100 mg twice daily</td>
                                       <td styleCode="Rrule">GZR</td>
                                       <td styleCode="Rrule">200 mg once daily</td>
                                       <td styleCode="Rrule">13</td>
                                       <td styleCode="Rrule">1.03 (0.96, 1.16)</td>
                                       <td styleCode="Rrule">0.97 (0.88, 1.08)</td>
                                       <td styleCode="Rrule">0.97 (0.81, 1.15)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" colspan="8">HIV Integrase Strand Transfer Inhibitor</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Dolutegravir</td>
                                       <td styleCode="Rrule">Dolutegravir 50 mg single-dose</td>
                                       <td styleCode="Rrule">EBR + GZR </td>
                                       <td styleCode="Rrule">50 mg + 200 mg once daily</td>
                                       <td styleCode="Rrule">12</td>
                                       <td styleCode="Rrule">1.16 (1.00, 1.34)</td>
                                       <td styleCode="Rrule">1.22 (1.05, 1.40)</td>
                                       <td styleCode="Rrule">1.14 (0.95, 1.36)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" rowspan="2">Raltegravir</td>
                                       <td styleCode="Rrule">Raltegravir 400 mg single-dose</td>
                                       <td styleCode="Rrule">EBR</td>
                                       <td styleCode="Rrule">50 mg single-dose</td>
                                       <td styleCode="Rrule">10</td>
                                       <td styleCode="Rrule">1.02 (0.81, 1.27)</td>
                                       <td styleCode="Rrule">1.09 (0.83, 1.44)</td>
                                       <td styleCode="Rrule">0.99 (0.80, 1.22)<footnote ID="t9f4">C12</footnote>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Rrule">Raltegravir 400 mg twice daily</td>
                                       <td styleCode="Rrule">GZR</td>
                                       <td styleCode="Rrule">200 mg once daily</td>
                                       <td styleCode="Rrule">11</td>
                                       <td styleCode="Rrule">1.43 (0.89, 2.30)</td>
                                       <td styleCode="Rrule">1.46 (0.78, 2.73)</td>
                                       <td styleCode="Rrule">1.47 (1.09, 2.00)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" colspan="8">HIV Non-Nucleoside Reverse Transcriptase Inhibitor</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" rowspan="2">Efavirenz</td>
                                       <td styleCode="Rrule">Efavirenz 600 mg once daily</td>
                                       <td styleCode="Rrule">EBR</td>
                                       <td styleCode="Rrule">50 mg once daily</td>
                                       <td styleCode="Rrule">7</td>
                                       <td styleCode="Rrule">0.82 (0.78, 0.86)</td>
                                       <td styleCode="Rrule">0.74 (0.67, 0.82)</td>
                                       <td styleCode="Rrule">0.91 (0.87, 0.96)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Rrule">Efavirenz 600 mg once daily</td>
                                       <td styleCode="Rrule">GZR</td>
                                       <td styleCode="Rrule">200 mg once daily</td>
                                       <td styleCode="Rrule">11</td>
                                       <td styleCode="Rrule">1.00 (0.96, 1.05)</td>
                                       <td styleCode="Rrule">1.03 (0.99, 1.08)</td>
                                       <td styleCode="Rrule">0.93 (0.88, 0.98)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Rilpivirine</td>
                                       <td styleCode="Rrule">Rilpivirine 25 mg once daily</td>
                                       <td styleCode="Rrule">EBR + GZR </td>
                                       <td styleCode="Rrule">50 mg + 200 mg once daily</td>
                                       <td styleCode="Rrule">19</td>
                                       <td styleCode="Rrule">1.13 (1.07, 1.20)</td>
                                       <td styleCode="Rrule">1.07 (0.97, 1.17)</td>
                                       <td styleCode="Rrule">1.16 (1.09, 1.23)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" colspan="8">HIV Nucleotide Reverse Transcriptase Inhibitor</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" rowspan="2">Tenofovir disoproxil fumarate</td>
                                       <td styleCode="Rrule">Tenofovir disoproxil fumarate 300 mg once daily</td>
                                       <td styleCode="Rrule">EBR</td>
                                       <td styleCode="Rrule">50 mg once daily</td>
                                       <td styleCode="Rrule">10</td>
                                       <td styleCode="Rrule">1.34 (1.23, 1.47)</td>
                                       <td styleCode="Rrule">1.47 (1.32, 1.63)</td>
                                       <td styleCode="Rrule">1.29 (1.18, 1.41)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Rrule">Tenofovir disoproxil fumarate 300 mg once daily</td>
                                       <td styleCode="Rrule">GZR</td>
                                       <td styleCode="Rrule">200 mg once daily</td>
                                       <td styleCode="Rrule">12</td>
                                       <td styleCode="Rrule">1.18 (1.09, 1.28)</td>
                                       <td styleCode="Rrule">1.14 (1.04, 1.25)</td>
                                       <td styleCode="Rrule">1.24 (1.10, 1.39)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" colspan="8">Immunosuppressant</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Cyclosporine</td>
                                       <td styleCode="Rrule">Cyclosporine 400 mg single-dose</td>
                                       <td styleCode="Rrule">EBR + GZR </td>
                                       <td styleCode="Rrule">50 mg + 200 mg once daily</td>
                                       <td styleCode="Rrule">14</td>
                                       <td styleCode="Rrule">0.96 (0.90, 1.02)</td>
                                       <td styleCode="Rrule">0.90 (0.85, 0.97)</td>
                                       <td styleCode="Rrule">1.00 (0.92, 1.08)<footnoteRef IDREF="t9f4"/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Mycophenolic acid</td>
                                       <td styleCode="Rrule">Mycophenolate mofetil 1000 mg single-dose</td>
                                       <td styleCode="Rrule">EBR + GZR </td>
                                       <td styleCode="Rrule">50 mg + 200 mg once daily</td>
                                       <td styleCode="Rrule">14</td>
                                       <td styleCode="Rrule">0.95 (0.87, 1.03)</td>
                                       <td styleCode="Rrule">0.85 (0.67, 1.07)</td>
                                       <td styleCode="Rrule">--</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Prednisolone</td>
                                       <td styleCode="Rrule">Prednisone 40 mg single-dose</td>
                                       <td styleCode="Rrule">EBR + GZR </td>
                                       <td styleCode="Rrule">50 mg + 200 mg once daily</td>
                                       <td styleCode="Rrule">14</td>
                                       <td styleCode="Rrule">1.08 (1.01, 1.16)</td>
                                       <td styleCode="Rrule">1.04 (0.99, 1.09)</td>
                                       <td styleCode="Rrule">--</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Prednisone</td>
                                       <td styleCode="Rrule">Prednisone 40 mg single-dose</td>
                                       <td styleCode="Rrule">EBR + GZR </td>
                                       <td styleCode="Rrule">50 mg + 200 mg once daily</td>
                                       <td styleCode="Rrule">14</td>
                                       <td styleCode="Rrule">1.08 (1.00, 1.17)</td>
                                       <td styleCode="Rrule">1.05 (1.00, 1.10)</td>
                                       <td styleCode="Rrule">--</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Tacrolimus</td>
                                       <td styleCode="Rrule">Tacrolimus<br/>2 mg single-dose</td>
                                       <td styleCode="Rrule">EBR + GZR </td>
                                       <td styleCode="Rrule">50 mg + 200 mg once daily</td>
                                       <td styleCode="Rrule">16</td>
                                       <td styleCode="Rrule">1.43 (1.24, 1.64)</td>
                                       <td styleCode="Rrule">0.60 (0.52, 0.69)</td>
                                       <td styleCode="Rrule">1.70 (1.49, 1.94)<footnoteRef IDREF="t9f4"/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" colspan="8">Oral Contraceptive</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" rowspan="2">Ethinyl estradiol (EE)</td>
                                       <td styleCode="Rrule" rowspan="4">0.03 mg EE/ 0.15 mg LNG single-dose</td>
                                       <td styleCode="Rrule">EBR</td>
                                       <td styleCode="Rrule">50 mg once daily</td>
                                       <td styleCode="Rrule">20</td>
                                       <td styleCode="Rrule">1.01 (0.97, 1.05)</td>
                                       <td styleCode="Rrule">1.10 (1.05, 1.16)</td>
                                       <td styleCode="Rrule">--</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Rrule">GZR</td>
                                       <td styleCode="Rrule">200 mg once daily</td>
                                       <td styleCode="Rrule">20</td>
                                       <td styleCode="Rrule">1.10 (1.05, 1.14)</td>
                                       <td styleCode="Rrule">1.05 (0.98, 1.12)</td>
                                       <td styleCode="Rrule">--</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" rowspan="2">Levonorgestrel (LNG)</td>
                                       <td styleCode="Rrule">EBR</td>
                                       <td styleCode="Rrule">50 mg once daily</td>
                                       <td styleCode="Rrule">20</td>
                                       <td styleCode="Rrule">1.14 (1.04, 1.24)</td>
                                       <td styleCode="Rrule">1.02 (0.95, 1.08)</td>
                                       <td styleCode="Rrule">--</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Rrule">GZR</td>
                                       <td styleCode="Rrule">200 mg once daily</td>
                                       <td styleCode="Rrule">20</td>
                                       <td styleCode="Rrule">1.23 (1.15, 1.32)</td>
                                       <td styleCode="Rrule">0.93 (0.84, 1.03)</td>
                                       <td styleCode="Rrule">--</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" colspan="8">Opioid Substitution Therapy</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" rowspan="2">Buprenorphine</td>
                                       <td styleCode="Rrule">Buprenorphine 8 mg/Naloxone 2 mg single-dose</td>
                                       <td styleCode="Rrule">EBR</td>
                                       <td styleCode="Rrule">50 mg once daily</td>
                                       <td styleCode="Rrule">15</td>
                                       <td styleCode="Rrule">0.98 (0.89, 1.08)</td>
                                       <td styleCode="Rrule">0.94 (0.82, 1.08)</td>
                                       <td styleCode="Rrule">0.98 (0.88, 1.09)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Rrule">Buprenorphine 8-24 mg/ Naloxone 2-6 mg once daily</td>
                                       <td styleCode="Rrule">GZR</td>
                                       <td styleCode="Rrule">200 mg once daily</td>
                                       <td styleCode="Rrule">12</td>
                                       <td styleCode="Rrule">0.98 (0.81, 1.19)</td>
                                       <td styleCode="Rrule">0.90 (0.76, 1.07)</td>
                                       <td styleCode="Rrule">--</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" rowspan="2">R-Methadone</td>
                                       <td styleCode="Rrule">Methadone 20-120 mg once daily</td>
                                       <td styleCode="Rrule">EBR</td>
                                       <td styleCode="Rrule">50 mg once daily</td>
                                       <td styleCode="Rrule">10</td>
                                       <td styleCode="Rrule">1.03 (0.92, 1.15)</td>
                                       <td styleCode="Rrule">1.07 (0.95, 1.20)</td>
                                       <td styleCode="Rrule">1.10 (0.96, 1.26)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Rrule">Methadone 20-150 mg once daily</td>
                                       <td styleCode="Rrule">GZR</td>
                                       <td styleCode="Rrule">200 mg once daily</td>
                                       <td styleCode="Rrule">12</td>
                                       <td styleCode="Rrule">1.09 (1.02, 1.17)</td>
                                       <td styleCode="Rrule">1.03 (0.96, 1.11)</td>
                                       <td styleCode="Rrule">--</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" rowspan="2">S-Methadone</td>
                                       <td styleCode="Rrule">Methadone 20-120 mg once daily</td>
                                       <td styleCode="Rrule">EBR</td>
                                       <td styleCode="Rrule">50 mg once daily</td>
                                       <td styleCode="Rrule">10</td>
                                       <td styleCode="Rrule">1.09 (0.94, 1.26)</td>
                                       <td styleCode="Rrule">1.09 (0.95, 1.25)</td>
                                       <td styleCode="Rrule">1.20 (0.98, 1.47)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Rrule">Methadone 20-150 mg once daily</td>
                                       <td styleCode="Rrule">GZR</td>
                                       <td styleCode="Rrule">200 mg once daily</td>
                                       <td styleCode="Rrule">12</td>
                                       <td styleCode="Rrule">1.23 (1.12, 1.35)</td>
                                       <td styleCode="Rrule">1.15 (1.07, 1.25)</td>
                                       <td styleCode="Rrule">--</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" colspan="8">Statin</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Atorvastatin</td>
                                       <td styleCode="Rrule">Atorvastatin 10 mg single-dose</td>
                                       <td styleCode="Rrule">EBR + GZR </td>
                                       <td styleCode="Rrule">50 mg + 200 mg once daily</td>
                                       <td styleCode="Rrule">16</td>
                                       <td styleCode="Rrule">1.94 (1.63, 2.33)</td>
                                       <td styleCode="Rrule">4.34 (3.10, 6.07)</td>
                                       <td styleCode="Rrule">0.21 (0.17, 0.26)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Pitavastatin</td>
                                       <td styleCode="Rrule">Pitavastatin 1 mg single-dose</td>
                                       <td styleCode="Rrule">GZR</td>
                                       <td styleCode="Rrule">200 mg once daily</td>
                                       <td styleCode="Rrule">9</td>
                                       <td styleCode="Rrule">1.11 (0.91, 1.34)</td>
                                       <td styleCode="Rrule">1.27 (1.07, 1.52)</td>
                                       <td styleCode="Rrule">--</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Pravastatin</td>
                                       <td styleCode="Rrule">Pravastatin 40 mg single-dose</td>
                                       <td styleCode="Rrule">EBR + GZR </td>
                                       <td styleCode="Rrule">50 mg + 200 mg once daily</td>
                                       <td styleCode="Rrule">12</td>
                                       <td styleCode="Rrule">1.33 (1.09, 1.64)<footnote ID="t9f5">N=10</footnote>
                                       </td>
                                       <td styleCode="Rrule">1.28 (1.05, 1.55)</td>
                                       <td styleCode="Rrule">--</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Rosuvastatin</td>
                                       <td styleCode="Rrule">Rosuvastatin 10 mg single-dose</td>
                                       <td styleCode="Rrule">EBR + GZR </td>
                                       <td styleCode="Rrule">50 mg + 200 mg once daily</td>
                                       <td styleCode="Rrule">12</td>
                                       <td styleCode="Rrule">2.26 (1.89, 2.69)<footnote ID="t9f6">N=8</footnote>
                                       </td>
                                       <td styleCode="Rrule">5.49 (4.29, 7.04)</td>
                                       <td styleCode="Rrule">0.98 (0.84, 1.13)</td>
                                    </tr>
                                 </tbody>
                              </table>
                           </text>
                           <effectiveTime value="20160128"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S12.4">
                     <id root="1717c486-6c13-460d-826b-0629ad3f7272"/>
                     <code code="49489-8" codeSystem="2.16.840.1.113883.6.1" displayName="MICROBIOLOGY SECTION"/>
                     <title>12.4	Microbiology</title>
                     <effectiveTime value="20160128"/>
                     <component>
                        <section>
                           <id root="fb460889-6afa-4da9-9122-a705d8e1d8f6"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Mechanism of Action</content>
                              </paragraph>
                              <paragraph>ZEPATIER combines two direct-acting antiviral agents with distinct mechanisms of action and non-overlapping resistance profiles to target HCV at multiple steps in the viral lifecycle.</paragraph>
                              <paragraph>Elbasvir is an inhibitor of HCV NS5A, which is essential for viral RNA replication and virion assembly. The mechanism of action of elbasvir has been characterized based on cell culture antiviral activity and drug resistance mapping studies.</paragraph>
                              <paragraph>Grazoprevir is an inhibitor of the HCV NS3/4A protease which is necessary for the proteolytic cleavage of the HCV encoded polyprotein (into mature forms of the NS3, NS4A, NS4B, NS5A, and NS5B proteins) and is essential for viral replication. In a biochemical assay, grazoprevir inhibited the proteolytic activity of the recombinant HCV genotype 1a, 1b, and 4a NS3/4A protease enzymes with IC<sub>50</sub> values of 7 pM, 4 pM, and 62 pM, respectively. </paragraph>
                           </text>
                           <effectiveTime value="20160128"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="ac8f0bad-9c0c-4182-9f80-1228f1732d29"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Antiviral Activity </content>
                              </paragraph>
                              <paragraph>In HCV replicon assays, the EC<sub>50</sub> values of elbasvir against full-length replicons from genotypes 1a, 1b, and 4, were 4 pM, 3 pM, and 0.3 pM, respectively. The median EC<sub>50</sub> values of elbasvir against chimeric replicons encoding NS5A sequences from clinical isolates were 5 pM for genotype 1a (range 3-9 pM; N=5), 9 pM for genotype 1b (range 5-10 pM; N=4), 0.2 pM for genotype 4a (range 0.2-0.2 pM; N=2), 3,600 pM for genotype 4b (range 17 pM-34,000 pM; N=3), 0.45 pM for genotype 4d (range 0.4-0.5 pM; N=2), 1.9 pM for genotype 4f (N=1), 36.3 pM for genotype 4g (range 0.6-72 pM; N=2), 0.6 pM for genotype 4m (range 0.4-0.7 pM; N=2), 2.2 pM for genotype 4o (N=1), and 0.5 pM for genotype 4q (N=1).</paragraph>
                              <paragraph>In HCV replicon assays, the EC<sub>50</sub> values of grazoprevir against full-length replicons from genotypes 1a, 1b, and 4, were 0.4 nM, 0.5 nM, and 0.3 nM, respectively. The median EC<sub>50</sub> values of grazoprevir against chimeric replicons encoding NS3/4A sequences from clinical isolates were 0.8 nM for genotype 1a (range 0.4-5.1 nM; N=10), 0.3 nM for genotype 1b (range 0.2-5.9 nM; N=9), 0.3 nM for genotype 4a (N=1), 0.16 nM for genotype 4b (range 0.11-0.2 nM; N=2), and 0.24 nM for genotype 4g (range 0.15-0.33 nM; N=2). </paragraph>
                           </text>
                           <effectiveTime value="20160128"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="9e1f8163-df6c-4379-998b-6f7595af5687"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Combination Antiviral Activity</content>
                              </paragraph>
                              <paragraph>Evaluation of elbasvir in combination with grazoprevir or ribavirin showed no antagonistic effect in reducing HCV RNA levels in replicon cells. Evaluation of grazoprevir in combination with ribavirin showed no antagonistic effect in reducing HCV RNA levels in replicon cells. </paragraph>
                           </text>
                           <effectiveTime value="20160128"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="28078670-a0e0-455c-99d4-16445c69bff2"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Resistance</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20160128"/>
                           <component>
                              <section>
                                 <id root="70702519-996d-44c2-9e49-53f030627721"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">In Cell Culture </content>
                                    </paragraph>
                                    <paragraph>HCV replicons with reduced susceptibility to elbasvir and grazoprevir have been selected in cell culture for genotypes 1a, 1b, and 4 which resulted in the emergence of resistance-associated amino acid substitutions in NS5A or NS3, respectively. The majority of amino acid substitutions in NS5A or NS3 selected in cell culture or identified in Phase 2b and 3 clinical trials were phenotypically characterized in genotype 1a, 1b, or 4 replicons. </paragraph>
                                    <paragraph>For elbasvir, in HCV genotype 1a replicons, single NS5A substitutions M28A/G/T, Q30D/E/H/K/R, L31M/V, H58D, and Y93C/H/N reduced elbasvir antiviral activity by 1.5- to 2,000-fold. In genotype 1b replicons, single NS5A substitutions L28M, L31F, and Y93H reduced elbasvir antiviral activity by 2- to 17-fold. In genotype 4 replicons, single NS5A substitutions L30S, M31V, and Y93H reduced elbasvir antiviral activity by 3- to 23-fold. In general, in HCV genotype 1a, 1b, or 4 replicons, combinations of elbasvir resistance-associated substitutions further reduced elbasvir antiviral activity.</paragraph>
                                    <paragraph>For grazoprevir, in HCV genotype 1a replicons, single NS3 substitutions Y56H, R155K, A156G/T/V, and D168A/E/G/N/S/V/Y reduced grazoprevir antiviral activity by 2- to 81-fold; V36L/M, Q80K/R, or V107I single substitutions had no impact on grazoprevir antiviral activity in cell culture. In genotype 1b replicons, single NS3 substitutions F43S, Y56F, V107I, A156S/T/V, and D168A/G/V reduced grazoprevir antiviral activity by 1.5- to 375-fold. In genotype 4 replicons, single NS3 substitutions D168A/V reduced grazoprevir antiviral activity by 110- to 320-fold. In general, in HCV genotype 1a, 1b, or 4 replicons, combinations of grazoprevir resistance-associated substitutions further reduced grazoprevir antiviral activity.</paragraph>
                                 </text>
                                 <effectiveTime value="20160128"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="1ff6fca5-109b-462b-9c43-35bcf4880727"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">In Clinical Studies</content>
                                    </paragraph>
                                    <paragraph>In a pooled analysis of subjects treated with regimens containing ZEPATIER or elbasvir + grazoprevir with or without ribavirin in Phase 2 and 3 clinical trials, resistance analyses of both drug targets were conducted for 50 subjects who experienced virologic failure and had sequence data available (6 with on-treatment virologic failure, 44 with post-treatment relapse). Treatment-emergent substitutions observed in the viral populations of these subjects based on HCV genotypes and subtypes are shown in <linkHtml href="#t10">Table 10</linkHtml>. Treatment-emergent NS5A substitutions were detected in 30/37 (81%) genotype 1a, 7/8 (88%) genotype 1b, and 5/5 (100%) genotype 4 infected subjects. The most common treatment-emergent NS5A substitutions in genotype 1a were at position Q30 (n=22). Treatment-emergent NS3 substitutions were detected in 29/37 (78%) genotype 1a, 2/8 (25%) genotype 1b, and 2/5 (40%) genotype 4 infected subjects. The most common treatment-emergent NS3 substitutions in genotype 1a were at position D168 (n=18). Treatment-emergent substitutions were detected in both HCV drug targets in 23/37 (62%) genotype 1a, 1/8 (13%) genotype 1b, and 2/5 (40%) genotype 4 infected subjects.</paragraph>
                                    <table width="80%" ID="t10">
                                       <caption>Table 10: Treatment-Emergent Amino Acid Substitutions Among Virologic Failures in the Pooled Analysis of ZEPATIER with and without Ribavirin Regimens in Phase 2 and Phase 3 Clinical Trials</caption>
                                       <col width="15%" align="center" valign="middle"/>
                                       <col width="29%" align="center" valign="middle"/>
                                       <col width="28%" align="center" valign="middle"/>
                                       <col width="28%" align="center" valign="middle"/>
                                       <thead>
                                          <tr>
                                             <th styleCode="Rrule Lrule" valign="bottom">Target</th>
                                             <th styleCode="Rrule">Genotype 1a<br/>N = 37</th>
                                             <th styleCode="Rrule">Genotype 1b<br/>N = 8</th>
                                             <th styleCode="Rrule">Genotype 4<br/>N = 5</th>
                                          </tr>
                                       </thead>
                                       <tbody>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Rrule Lrule">NS5A</td>
                                             <td styleCode="Rrule">M28A/G/T, Q30H/K/R/Y, L31F/M/V, H58D, Y93H/N/S</td>
                                             <td styleCode="Rrule">L28M, L31F/V, Y93H</td>
                                             <td styleCode="Rrule">L28S/T, M31I/V, P58D, Y93H</td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule">NS3</td>
                                             <td styleCode="Rrule">V36L/M, Y56H, V107I, R155I/K, A156G/T/V, V158A, D168A/G/N/V/Y</td>
                                             <td styleCode="Rrule">Y56F, V107I, A156T</td>
                                             <td styleCode="Rrule">A156M/T/V, D168A/G, V170I</td>
                                          </tr>
                                       </tbody>
                                    </table>
                                 </text>
                                 <effectiveTime value="20160128"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="c9f3451b-c12a-4cf5-8819-10b6f000347f"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Persistence of Resistance-Associated Substitutions</content>
                              </paragraph>
                              <paragraph>The persistence of elbasvir and grazoprevir treatment-emergent amino acid substitutions in NS5A, and NS3, respectively, was assessed in HCV genotype 1-infected subjects in Phase 2 and 3 trials whose virus had treatment-emergent resistance-associated substitutions in the drug target, and with available data through at least 24 weeks post-treatment using population nucleotide sequence analysis. </paragraph>
                              <paragraph>Viral populations with treatment-emergent NS5A resistance-associated substitutions were generally more persistent than those with NS3 resistance-associated substitutions. Among genotype 1a-infected subjects, NS5A resistance-associated substitutions persisted at detectable levels at follow-up week 12 in 95% (35/37) of subjects and in 100% (9/9) of subjects with follow-up week 24 data. Among genotype 1b-infected subjects, NS5A resistance-associated substitutions persisted at detectable levels in 100% (7/7) of subjects at follow-up week 12 and in 100% (3/3) of subjects with follow-up week 24 data.</paragraph>
                              <paragraph>Among genotype 1a-infected subjects, NS3 resistance-associated substitutions persisted at detectable levels at follow-up week 24 in 31% (4/13) of subjects. Among genotype 1b-infected subjects, NS3 resistance-associated substitutions persisted at detectable levels at follow-up week 24 in 50% (1/2) of subjects.</paragraph>
                              <paragraph>Due to the limited number of genotype 4-infected subjects with treatment-emergent NS5A and NS3 resistance-associated substitutions, trends in persistence of treatment-emergent substitutions in this genotype could not be established. </paragraph>
                              <paragraph>The lack of detection of a virus containing a resistance-associated substitution does not necessarily indicate that viral populations carrying that substitution have declined to a background level that may have existed prior to treatment. The long-term clinical impact of the emergence or persistence of virus containing ZEPATIER-resistance-associated substitutions is unknown.</paragraph>
                           </text>
                           <effectiveTime value="20160128"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="e6f1d417-464c-4708-987c-a32fd8141f5d"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Effect of Baseline HCV Amino Acid Polymorphisms on Treatment Response in Genotype 1-Infected Subjects </content>
                              </paragraph>
                              <paragraph>Analyses using population nucleotide sequencing were conducted to explore the association between NS5A or NS3 amino acid polymorphisms and treatment response among treatment-naÃ¯ve and treatment-experienced genotype 1-infected subjects. Baseline NS5A polymorphisms at resistance-associated positions (focusing on any change from subtype reference at NS5A amino acid positions 28, 30, 31, or 93) were evaluated. Baseline NS3 polymorphisms at positions 36, 54, 55, 56, 80, 107, 122, 132, 155, 156, 158, 168, 170, or 175 were evaluated. Analyses of SVR12 rates pooled data from subjects naÃ¯ve to direct-acting antivirals and who received ZEPATIER with or without ribavirin in Phase 3 clinical trials, and censored subjects who did not achieve SVR12 for reasons unrelated to virologic failure.</paragraph>
                           </text>
                           <effectiveTime value="20160128"/>
                           <component>
                              <section>
                                 <id root="e3a45fd5-4145-4c37-9cf5-e0fdb8e477ed"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Genotype 1a</content>
                                    </paragraph>
                                    <paragraph>In genotype 1a-infected subjects, the presence of one or more HCV NS5A amino acid polymorphisms at position M28, Q30, L31, or Y93 was associated with reduced efficacy of ZEPATIER for 12 weeks (<linkHtml href="#t11">Table 11</linkHtml>), regardless of prior treatment history or cirrhosis status. The prevalence of polymorphisms at any of these positions in genotype 1a-infected subjects was 11% (62/561) overall, and 12% (37/309) specifically for subjects in the U.S. across Phase 2 and Phase 3 clinical trials evaluating ZEPATIER for 12 weeks or ZEPATIER plus ribavirin for 16 weeks. The prevalence of polymorphisms at these positions in genotype 1a-infected subjects was 6% (35/561) at position M28, 2% (11/561) at position Q30, 3% (15/561) at position L31, and 2% (10/561) at position Y93. Polymorphisms at NS5A position H58 were common (10%) and were not associated with reduced ZEPATIER efficacy, except for a single virologic failure subject whose virus had baseline M28V and H58D polymorphisms.</paragraph>
                                    <paragraph>The SVR12 rates for subjects treated with ZEPATIER for 12 weeks were 88% (29/33) for subjects with M28V/T/L polymorphisms (n=29, 3, and 1, respectively), 40% (4/10) for subjects with Q30H/R/L polymorphisms (n=5, 3, and 2, respectively), 38% (5/13) for subjects with an L31M polymorphism, and 63% (5/8) for subjects with Y93C/H/N/S polymorphisms (n=3, 3, 1, and 1, respectively). Although data are limited, among genotype 1a-infected subjects with these NS5A polymorphisms who received ZEPATIER plus ribavirin for 16 weeks, six out of six subjects achieved SVR12. The specific NS5A polymorphisms observed in subjects treated with ZEPATIER plus ribavirin for 16 weeks included M28V (n=2), Q30H (n=1), L31M (n=2), or Y93C/H (n=1 each). </paragraph>
                                    <table width="80%" ID="t11">
                                       <caption>Table 11: SVR12 in HCV Genotype 1a-Infected Subjects without or with Baseline NS5A Polymorphisms</caption>
                                       <col width="40%" align="left" valign="top"/>
                                       <col width="25%" align="center" valign="bottom"/>
                                       <col width="35%" align="center" valign="bottom"/>
                                       <thead>
                                          <tr>
                                             <th styleCode="Rrule Lrule" valign="middle">NS5A Polymorphism Status</th>
                                             <th styleCode="Rrule" valign="middle">ZEPATIER 12 Weeks<br/>SVR12 % (n/N)</th>
                                             <th styleCode="Rrule" valign="middle">ZEPATIER + RBV 16 Weeks<br/>SVR12 % (n/N)</th>
                                          </tr>
                                       </thead>
                                       <tbody>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Rrule Lrule">Without baseline NS5A polymorphism <br/>(M28, Q30, L31, or Y93)</td>
                                             <td styleCode="Rrule">98% (441/450)</td>
                                             <td styleCode="Rrule">100% (49/49)</td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule">With baseline NS5A polymorphism<br/>(M28<footnote ID="t11f1">Any change from GT1a reference.</footnote>, Q30<footnoteRef IDREF="t11f1"/>, L31<footnoteRef IDREF="t11f1"/>, or Y93<footnoteRef IDREF="t11f1"/>)</td>
                                             <td styleCode="Rrule">70% (39/56)</td>
                                             <td styleCode="Rrule">100% (6/6)</td>
                                          </tr>
                                       </tbody>
                                    </table>
                                    <paragraph>There are insufficient data to determine the impact of HCV NS5A amino acid polymorphisms in treatment-experienced subjects who failed prior PegIFN + RBV + HCV protease inhibitor therapy and received ZEPATIER with ribavirin.</paragraph>
                                    <paragraph>In genotype 1a-infected subjects, the NS3 Q80K polymorphism did not impact treatment response. Polymorphisms at other NS3 resistance-associated positions were uncommon and were not associated with reduced treatment efficacy.</paragraph>
                                 </text>
                                 <effectiveTime value="20160128"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="0469ff5f-ce56-4cd3-a2b1-d02b68817717"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Genotype 1b</content>
                                    </paragraph>
                                    <paragraph>In genotype 1b-infected subjects treated with ZEPATIER for 12 weeks, SVR12 rates (non-virologic failure-censored) were 94% (48/51) and 99% (247/248) for those with and without one or more NS5A polymorphisms at position 28, 30, 31, or 93.</paragraph>
                                    <paragraph>In genotype 1b-infected subjects, baseline NS3 polymorphisms did not impact treatment response.</paragraph>
                                 </text>
                                 <effectiveTime value="20160128"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="40908b5b-182b-4ef2-bd93-2a30ca5679ae"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Effect of Baseline HCV Polymorphisms on Treatment Response in Genotype 4-Infected Subjects</content>
                              </paragraph>
                              <paragraph>Phylogenetic analysis of HCV sequences from genotype 4-infected subjects (n=71) in the pooled analyses of subjects (non-virologic failure-censored) treated with regimens containing ZEPATIER or elbasvir + grazoprevir with or without ribavirin in Phase 2 and 3 clinical trials identified 4 HCV genotype 4 subtypes (4a, 4d, 4k, 4o). Most subjects were infected with either subtype 4a (42%) or 4d (51%); 1 to 2 subjects were infected with each of the other genotype 4 subtypes. Among subjects enrolled at U.S. study sites, 11/13 (85%) were infected with HCV subtype 4a. There were two subjects infected with HCV subtype 4d who experienced virologic failure with the regimen containing grazoprevir and elbasvir. </paragraph>
                              <paragraph>In genotype 4-infected subjects, SVR12 rates for subjects with baseline NS5A polymorphisms (any change from reference at NS5A amino acid positions 28, 30, 31, 58, and 93 by population nucleotide sequencing) were 100% (28/28) and for subjects without baseline NS5A polymorphisms were 95% (41/43). </paragraph>
                              <paragraph>In genotype 4-infected subjects, SVR12 rates for subjects with baseline NS3 polymorphisms (any change from reference at NS3 amino acid positions 36, 54, 55, 56, 80, 107, 122, 132, 155, 156, 158, 168, 170, and 175 by population nucleotide sequencing) were 100% (18/18) and for subjects without baseline NS3 polymorphisms were 96% (51/53). </paragraph>
                           </text>
                           <effectiveTime value="20160128"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="2b762879-398c-4616-834b-1e9fad89d432"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Cross Resistance </content>
                              </paragraph>
                              <paragraph>Cross resistance is possible among NS5A inhibitors and NS3/4A protease inhibitors by class. Elbasvir and grazoprevir are fully active against viral populations with substitutions conferring resistance to NS5B inhibitors. </paragraph>
                              <paragraph>In the C-SALVAGE trial, subjects with genotype 1 infection who had failed prior treatment with boceprevir (n=28), simeprevir (n=8), or telaprevir (n=43) in combination with PegIFN + RBV received EBR 50 mg once daily + GZR 100 mg once daily + RBV for 12 weeks. There are limited data to determine the impact of HCV NS3 resistance-associated substitutions detected at baseline in treatment-experienced subjects who failed prior PegIFN + RBV + HCV protease inhibitor therapy and received ZEPATIER with ribavirin. SVR was achieved in 88% (21/24) of genotype 1a and genotype 1b infected subjects with NS3 resistance-associated substitutions detected at baseline. Specific NS3 substitutions observed at baseline included one or more of the following: V36L/M (n=8), T54S (n=4), S122G/T (n=9), R155K/T (n=9), A156S/T (n=1), and D168E/N (n=3). SVR was 100% (55/55) in subjects without baseline NS3 resistance substitutions. The 3 virologic failure subjects had the following NS3 or NS5A substitutions/polymorphisms at baseline: NS3 R155T/D168N, NS3 R155K plus NS5A H58D, and NS3 T54S plus NS5A L31M.</paragraph>
                              <paragraph>The efficacy of ZEPATIER has not been established in patients who have previously failed treatment with other regimens that included an NS5A inhibitor. </paragraph>
                           </text>
                           <effectiveTime value="20160128"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S13">
               <id root="fa934186-257c-4145-a204-f8f4c34968a9"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20160128"/>
               <component>
                  <section ID="S13.1">
                     <id root="903174bb-2e5e-4d77-9151-2a644027c131"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1	Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <effectiveTime value="20160128"/>
                     <component>
                        <section>
                           <id root="a00b66cf-9fe3-422d-b69e-176ce441ecf0"/>
                           <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Carcinogenesis and Mutagenesis </content>
                              </paragraph>
                              <paragraph>Elbasvir and grazoprevir were not genotoxic in a battery of <content styleCode="italics">in vitro</content> or <content styleCode="italics">in vivo</content> assays, including microbial mutagenesis, chromosomal aberration in Chinese Hamster Ovary cells, and in <content styleCode="italics">in vivo</content> rat micronucleus assays. </paragraph>
                              <paragraph>Carcinogenicity studies with elbasvir or grazoprevir have not been conducted.</paragraph>
                              <paragraph>If ZEPATIER is administered in a regimen containing ribavirin, the information for ribavirin on carcinogenesis and mutagenesis also applies to this combination regimen. Refer to the ribavirin prescribing information for information on carcinogenesis and mutagenesis.</paragraph>
                           </text>
                           <effectiveTime value="20160128"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="56e55c8d-6a65-4349-b4b4-4ef0b31d0360"/>
                           <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Impairment of Fertility </content>
                              </paragraph>
                              <paragraph>No effects on mating, female or male fertility, or early embryonic development were observed in rats at up to the highest dose tested. Systemic exposures (AUC) to elbasvir and grazoprevir were approximately 8 and 114 times, respectively, the exposure in humans at the recommended human dose. </paragraph>
                              <paragraph>If ZEPATIER is administered with ribavirin, the information for ribavirin on impairment of fertility also applies to this combination regimen. Refer to the ribavirin prescribing information for information on impairment of fertility.</paragraph>
                           </text>
                           <effectiveTime value="20160128"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S14">
               <id root="cc2bdd60-1d49-4cd1-a267-116c9a1092d1"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <effectiveTime value="20160128"/>
               <component>
                  <section ID="S14.1">
                     <id root="fec07c66-4995-4e3d-846a-0ed8ab21397e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.1	Overview of Clinical Trials </title>
                     <text>
                        <paragraph>The efficacy of ZEPATIER was assessed in 2 placebo-controlled trials and 4 uncontrolled Phase 2 and 3 clinical trials in 1401 subjects with genotype (GT) 1, 4, or 6 chronic hepatitis C virus infection with compensated liver disease (with or without cirrhosis). An overview of the 6 trials (n=1373) contributing to the assessment of efficacy in genotype 1 or 4 is provided in <linkHtml href="#t12">Table 12</linkHtml>. C-EDGE TN, C-EDGE COINFECTION, C-SCAPE, and C-EDGE TE also included subjects with genotype 6 HCV infection (n=28). Because ZEPATIER is not indicated for genotype 6 infection, results in patients with genotype 6 infection are not included in Clinical Studies (14).</paragraph>
                        <table width="80%" ID="t12">
                           <caption>Table 12: Trials Conducted with ZEPATIER</caption>
                           <col width="20%" align="left" valign="top"/>
                           <col width="30%" align="center" valign="top"/>
                           <col width="50%" align="left" valign="top"/>
                           <thead>
                              <tr>
                                 <th styleCode="Lrule Rrule">Trial</th>
                                 <th styleCode="Rrule">Population</th>
                                 <th styleCode="Rrule" align="center">Study Groups and Duration<br/>(Number of Subjects Treated)</th>
                              </tr>
                           </thead>
                           <tfoot>
                              <tr>
                                 <td align="left" valign="top" colspan="3">GT = Genotype</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" colspan="3">TN = Treatment-NaÃ¯ve</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" colspan="3">TE = Treatment-Experienced (failed prior treatment with interferon [IFN] or peginterferon alfa [PegIFN] with or without ribavirin [RBV] or were intolerant to prior therapy).</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">C-EDGE TN<br/>(double-blind)</td>
                                 <td styleCode="Rrule">GT 1, 4<br/>TN with or without cirrhosis</td>
                                 <td styleCode="Rrule">
                                    <list listType="unordered" styleCode="Disc">
                                       <item>ZEPATIER for 12 weeks (N=306)</item>
                                       <item>Placebo for 12 weeks (N=102)</item>
                                    </list>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">C-EDGE COINFECTION<br/>(open-label)</td>
                                 <td styleCode="Rrule">GT 1, 4<br/>TN with or without cirrhosis<br/>HCV/HIV-1 co-infection</td>
                                 <td styleCode="Rrule">
                                    <list listType="unordered" styleCode="Disc">
                                       <item>ZEPATIER for 12 weeks (N=217)</item>
                                    </list>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">C-SURFER<br/>(double-blind)</td>
                                 <td styleCode="Rrule">GT 1<br/>TN or TE with or without cirrhosis<br/>Severe Renal Impairment including Hemodialysis</td>
                                 <td styleCode="Rrule">
                                    <list listType="unordered" styleCode="Disc">
                                       <item>EBR<footnote ID="t12f1">EBR = elbasvir 50 mg; GZR = grazoprevir 100 mg; EBR + GZR = co-administered as single agents.</footnote> + GZR<footnoteRef IDREF="t12f1"/> for 12 weeks (N=122)</item>
                                       <item>Placebo for 12 weeks (N=113)</item>
                                    </list>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">C-SCAPE<br/>(open-label)</td>
                                 <td styleCode="Rrule">GT 4<br/>TN without cirrhosis</td>
                                 <td styleCode="Rrule">
                                    <list listType="unordered" styleCode="Disc">
                                       <item>EBR<footnoteRef IDREF="t12f1"/> + GZR<footnoteRef IDREF="t12f1"/> for 12 weeks (N=10)</item>
                                       <item>EBR<footnoteRef IDREF="t12f1"/> + GZR<footnoteRef IDREF="t12f1"/> + RBV for 12 weeks (N=10)</item>
                                    </list>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">C-EDGE TE<br/>(open-label)</td>
                                 <td styleCode="Rrule">GT 1, 4<br/>TE with or without cirrhosis<br/>HCV/HIV-1 co-infection</td>
                                 <td styleCode="Rrule">
                                    <list listType="unordered" styleCode="Disc">
                                       <item>ZEPATIER for 12 or 16 weeks (N=105, and 101, respectively)</item>
                                       <item>ZEPATIER + RBV for 12 or 16 weeks (N=104 and 104, respectively)</item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">C-SALVAGE<br/>(open-label)</td>
                                 <td styleCode="Rrule">GT 1<br/>TE with HCV protease inhibitor regimen<footnote ID="t12f2">Failed prior treatment with boceprevir, telaprevir, or simeprevir in combination with PegIFN + RBV.</footnote> with or without cirrhosis</td>
                                 <td styleCode="Rrule">
                                    <list listType="unordered" styleCode="Disc">
                                       <item>EBR<footnoteRef IDREF="t12f1"/> + GZR<footnoteRef IDREF="t12f1"/> + RBV for 12 weeks (N=79)</item>
                                    </list>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>ZEPATIER was administered once daily by mouth in these trials. For subjects who received ribavirin (RBV), the RBV dosage was weight-based (less than 66 kg = 800 mg per day, 66 to 80 kg = 1000 mg per day, 81 to 105 kg = 1200 mg per day, greater than 105 kg = 1400 mg per day) administered by mouth in two divided doses with food. </paragraph>
                        <paragraph>Sustained virologic response (SVR) was the primary endpoint in all trials and was defined as HCV RNA less than lower limit of quantification (LLOQ) at 12 weeks after the cessation of treatment (SVR12). Serum HCV RNA values were measured during these clinical trials using the COBAS AmpliPrep/COBAS Taqman HCV test (version 2.0) with an LLOQ of 15 HCV RNA IU per mL, with the exception of C-SCAPE where the assay had an LLOQ of 25 HCV RNA IU per mL.</paragraph>
                     </text>
                     <effectiveTime value="20160128"/>
                  </section>
               </component>
               <component>
                  <section ID="S14.2">
                     <id root="e4986823-d2cd-4bf4-bc64-79925d5f4ebe"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.2	Clinical Trials in Treatment-NaÃ¯ve Subjects with Genotype 1 HCV (C-EDGE TN and C-EDGE COINFECTION)</title>
                     <text>
                        <paragraph>The efficacy of ZEPATIER in treatment-naÃ¯ve subjects with genotype 1 chronic hepatitis C virus infection with or without cirrhosis was demonstrated in the C-EDGE TN and C-EDGE COINFECTION trials. </paragraph>
                        <paragraph>C-EDGE TN was a randomized, double-blind, placebo-controlled trial in treatment-naÃ¯ve subjects with genotype 1 or 4 infection with or without cirrhosis. Subjects were randomized in a 3:1 ratio to: ZEPATIER for 12 weeks (immediate treatment group) or placebo for 12 weeks followed by open-label treatment with ZEPATIER for 12 weeks (deferred treatment group). Among subjects with genotype 1 infection randomized to the immediate treatment group, the median age was 55 years (range: 20 to 78); 56% of the subjects were male; 61% were White; 20% were Black or African American; 8% were Hispanic or Latino; mean body mass index was 26 kg/m<sup>2</sup>; 72% had baseline HCV RNA levels greater than 800,000 IU per mL; 24% had cirrhosis; 67% had non-C/C IL28B alleles (CT or TT); and 55% had genotype 1a and 45% had genotype 1b chronic HCV infection. </paragraph>
                        <paragraph>C-EDGE COINFECTION was an open-label, single-arm trial in treatment-naÃ¯ve HCV/HIV-1 co-infected subjects with genotype 1 or 4 infection with or without cirrhosis. Subjects received ZEPATIER for 12 weeks. Among subjects with genotype 1 infection, the median age was 50 years (range: 21 to 71); 85% of the subjects were male; 75% were White; 19% were Black or African American; 6% were Hispanic or Latino; mean body mass index was 25 kg per m<sup>2</sup>; 59% had baseline HCV RNA levels greater than 800,000 IU per mL; 16% had cirrhosis; 65% had non-C/C IL28B alleles (CT or TT); and 76% had genotype 1a, 23% had genotype 1b, and 1% had genotype 1-Other chronic HCV infection. </paragraph>
                        <paragraph>
                           <linkHtml href="#t13">Table 13</linkHtml> presents treatment outcomes for ZEPATIER in treatment-naÃ¯ve subjects with genotype 1 infection from C-EDGE TN (immediate treatment group) and C-EDGE COINFECTION. For treatment outcomes for ZEPATIER in genotype 4 infection, <content styleCode="italics">[see <linkHtml href="#S14.5">Clinical Studies (14.5)</linkHtml>]</content>.</paragraph>
                        <table width="75%" ID="t13">
                           <caption>Table 13: C-EDGE TN and C-EDGE COINFECTION: SVR12 in Treatment-NaÃ¯ve Subjects with or without Cirrhosis with Genotype 1 HCV Treated with ZEPATIER for 12 Weeks</caption>
                           <col width="46%" align="left" valign="bottom"/>
                           <col width="27%" align="center" valign="bottom"/>
                           <col width="27%" align="center" valign="bottom"/>
                           <thead>
                              <tr styleCode="Botrule">
                                 <th styleCode="Rrule Lrule" align="center" valign="top">Trial</th>
                                 <th styleCode="Rrule" valign="top">C-EDGE TN<br/>(Immediate Treatment Group)</th>
                                 <th styleCode="Rrule" valign="top">C-EDGE<br/>COINFECTION<br/>(HCV/HIV-1<br/>Co-Infection)</th>
                              </tr>
                              <tr>
                                 <th styleCode="Rrule Lrule" align="center" valign="top">Regimen</th>
                                 <th styleCode="Rrule" valign="top">ZEPATIER<br/>12 Weeks<br/>N=288</th>
                                 <th styleCode="Rrule" valign="top">ZEPATIER<br/>12 Weeks<br/>N=189</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Rrule Lrule">SVR in Genotype 1 </td>
                                 <td styleCode="Rrule">95% (273/288)</td>
                                 <td styleCode="Rrule">95% (179/189)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Rrule Lrule" colspan="3" align="left">Outcome for subjects without SVR</td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule">Â Â On-treatment Virologic Failure<footnote>Includes subjects with virologic breakthrough.</footnote>
                                 </td>
                                 <td styleCode="Rrule">&lt;1% (1/288)</td>
                                 <td styleCode="Rrule">0% (0/189)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule">Â Â Relapse</td>
                                 <td styleCode="Rrule">3% (10/288)</td>
                                 <td styleCode="Rrule">3% (6/189)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Rrule Lrule">Â Â Other<footnote>Other includes subjects who discontinued due to adverse event, lost to follow-up, or subject withdrawal.</footnote>
                                 </td>
                                 <td styleCode="Rrule">1% (4/288)</td>
                                 <td styleCode="Rrule">2% (4/189)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Rrule Lrule" colspan="3" align="left">SVR by Genotype 1 Subtypes</td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule">Â Â GT 1a<footnote>For the impact of baseline NS5A polymorphisms on SVR12, <content styleCode="italics">[see <linkHtml href="#S12.4">Microbiology (12.4)</linkHtml>], <linkHtml href="#t11">Table 11</linkHtml>
                                       </content>.</footnote>
                                 </td>
                                 <td styleCode="Rrule">92% (144/157)</td>
                                 <td styleCode="Rrule">94% (136/144)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Rrule Lrule">Â Â GT 1b<footnote>Includes genotype 1 subtypes other than 1a or 1b.</footnote>
                                 </td>
                                 <td styleCode="Rrule">98% (129/131)</td>
                                 <td styleCode="Rrule">96% (43/45)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Rrule Lrule" colspan="3" align="left">SVR by Cirrhosis status</td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule">Â Â Non-cirrhotic</td>
                                 <td styleCode="Rrule">94% (207/220)</td>
                                 <td styleCode="Rrule">94% (148/158)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule">Â Â Cirrhotic</td>
                                 <td styleCode="Rrule">97% (66/68)</td>
                                 <td styleCode="Rrule">100% (31/31)</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20160128"/>
                  </section>
               </component>
               <component>
                  <section ID="S14.3">
                     <id root="276e3387-5242-4b2e-9483-8c071d3120d2"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.3	Clinical Trials in Treatment-Experienced Subjects with Genotype 1 HCV </title>
                     <effectiveTime value="20160128"/>
                     <component>
                        <section>
                           <id root="09fbf673-484a-4dab-8bf4-5108dc5156de"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Treatment-Experienced Subjects who Failed Prior PegIFN with RBV Therapy (C-EDGE TE)</content>
                              </paragraph>
                              <paragraph>C-EDGE TE was a randomized, open-label comparative trial in subjects with genotype 1 or 4 infection, with or without cirrhosis, with or without HCV/HIV-1 co-infection, who had failed prior therapy with PegIFN + RBV therapy. Subjects were randomized in a 1:1:1:1 ratio to one of the following treatment groups: ZEPATIER for 12 weeks, ZEPATIER + RBV for 12 weeks, ZEPATIER for 16 weeks, or ZEPATIER + RBV for 16 weeks. Among subjects with genotype 1 infection, the median age was 57 years (range: 19 to 77); 64% of the subjects were male; 67% were White; 18% were Black or African American; 9% were Hispanic or Latino; mean body mass index was 28 kg/m<sup>2</sup>; 78% had baseline HCV RNA levels greater than 800,000 IU/mL; 34% had cirrhosis; 79% had non-C/C IL28B alleles (CT or TT); and 60% had genotype 1a, 39% had genotype 1b, and 1% had genotype 1-Other chronic HCV infection.</paragraph>
                              <paragraph>Treatment outcomes in genotype 1 subjects treated with ZEPATIER for 12 weeks or ZEPATIER with RBV for 16 weeks are presented in <linkHtml href="#t14">Table 14</linkHtml>. Treatment outcomes with ZEPATIER with RBV for 12 weeks or without RBV for 16 weeks are not shown because these regimens are not recommended in PegIFN/RBV-experienced genotype 1 patients. For treatment outcomes for ZEPATIER in genotype 4 infection, <content styleCode="italics">[see <linkHtml href="#S14.5">Clinical Studies (14.5)</linkHtml>]</content>.</paragraph>
                              <table width="75%" ID="t14">
                                 <caption>Table 14: C-EDGE TE: SVR12 in Treatment-Experienced Subjects who Failed Prior PegIFN with RBV with or without Cirrhosis, with or without HCV/HIV-1 Co-infection with Genotype 1 HCV Treated with ZEPATIER for 12 Weeks or ZEPATIER with Ribavirin for 16 Weeks</caption>
                                 <col width="46%" align="left" valign="bottom"/>
                                 <col width="27%" align="center" valign="bottom"/>
                                 <col width="27%" align="center" valign="bottom"/>
                                 <thead>
                                    <tr>
                                       <th styleCode="Rrule Lrule" align="center" valign="top">Regimen</th>
                                       <th styleCode="Rrule" valign="top">ZEPATIER<br/>12 weeks<br/>N=96</th>
                                       <th styleCode="Rrule" valign="top">ZEPATIER + RBV<br/>16 weeks<br/>N=96</th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Rrule Lrule">SVR in Genotype 1 </td>
                                       <td styleCode="Rrule">94% (90/96)</td>
                                       <td styleCode="Rrule">97% (93/96)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Rrule Lrule" colspan="3" align="left">Outcome for subjects without SVR</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Rrule Lrule">Â Â On-treatment Virologic Failure<footnote>Includes subjects with virologic breakthrough or rebound.</footnote>
                                       </td>
                                       <td styleCode="Rrule">0% (0/96)</td>
                                       <td styleCode="Rrule">0% (0/96)</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Rrule Lrule">Â Â Relapse</td>
                                       <td styleCode="Rrule">5% (5/96)</td>
                                       <td styleCode="Rrule">0% (0/96)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Rrule Lrule">Â Â Other<footnote>Other includes subjects who discontinued due to adverse event, lost to follow-up, or subject withdrawal.</footnote>
                                       </td>
                                       <td styleCode="Rrule">1% (1/96)</td>
                                       <td styleCode="Rrule">3% (3/96)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Rrule Lrule" colspan="3" align="left">SVR by Genotype 1 Subtypes</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Rrule Lrule">Â Â GT 1a<footnote>For the impact of baseline NS5A polymorphisms on SVR, <content styleCode="italics">[see <linkHtml href="#S12.4">Microbiology (12.4)</linkHtml>], <linkHtml href="#t11">Table 11</linkHtml>
                                             </content>.</footnote>
                                       </td>
                                       <td styleCode="Rrule">90% (55/61)</td>
                                       <td styleCode="Rrule">95% (55/58)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Rrule Lrule">Â Â GT 1b<footnote>Includes genotype 1 subtypes other than 1a or 1b.</footnote>
                                       </td>
                                       <td styleCode="Rrule">100% (35/35)</td>
                                       <td styleCode="Rrule">100% (38/38)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Rrule Lrule" colspan="3" align="left">SVR by Cirrhosis status</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Rrule Lrule">Â Â Non-cirrhotic</td>
                                       <td styleCode="Rrule">94% (61/65)</td>
                                       <td styleCode="Rrule">95% (61/64)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Rrule Lrule">Â Â Cirrhotic</td>
                                       <td styleCode="Rrule">94% (29/31)</td>
                                       <td styleCode="Rrule">100% (32/32)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Rrule Lrule" colspan="3" align="left">SVR by Response to Prior HCV Therapy</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Rrule Lrule">Â Â On-treatment Virologic Failure<footnote>Includes prior null responders and partial responders. </footnote>
                                       </td>
                                       <td styleCode="Rrule">90% (57/63)</td>
                                       <td styleCode="Rrule">95% (58/61)</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Rrule Lrule">Â Â Relapser</td>
                                       <td styleCode="Rrule">100% (33/33)</td>
                                       <td styleCode="Rrule">100% (35/35)</td>
                                    </tr>
                                 </tbody>
                              </table>
                           </text>
                           <effectiveTime value="20160128"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="84069ab4-d4ce-4a23-aa8e-e6f641b02555"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Treatment-Experienced Subjects who Failed Prior PegIFN + RBV + HCV Protease Inhibitor Therapy (C-SALVAGE)</content>
                              </paragraph>
                              <paragraph>C-SALVAGE was an open-label single-arm trial in subjects with genotype 1 infection, with or without cirrhosis, who had failed prior treatment with boceprevir, simeprevir, or telaprevir in combination with pegIFN + RBV. Subjects received EBR 50 mg once daily + GZR 100 mg once daily + RBV for 12 weeks. Subjects had a median age of 55 years (range: 23 to 75); 58% of the subjects were male; 97% were White; 3% were Black or African American; 15% were Hispanic or Latino; mean body mass index was 28 kg/m<sup>2</sup>; 63% had baseline HCV RNA levels greater than 800,000 IU/mL; 43% had cirrhosis; and 97% had non-C/C IL28B alleles (CT or TT); 46% had baseline NS3 resistance-associated substitutions.</paragraph>
                              <paragraph>Overall SVR was achieved in 96% (76/79) of subjects receiving EBR + GZR + RBV for 12 weeks. Four percent (3/79) of subjects did not achieve SVR due to relapse. Treatment outcomes were consistent in genotype 1a and genotype 1b subjects, in subjects with different response to previous HCV therapy, and in subjects with or without cirrhosis. Treatment outcomes were generally consistent in subjects with or without NS3 resistance-associated substitutions at baseline, although limited data are available for subjects with specific NS3 resistance-associated substitutions <content styleCode="italics">[see <linkHtml href="#S12.4">Microbiology (12.4)</linkHtml>]</content>.</paragraph>
                           </text>
                           <effectiveTime value="20160128"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S14.4">
                     <id root="2fc7ee39-eb5c-4306-9129-d2ecac38d47b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.4	Clinical Trial in Subjects with Genotype 1 HCV and Severe Renal Impairment including Subjects on Hemodialysis (C-SURFER)</title>
                     <text>
                        <paragraph>C-SURFER was a randomized, double-blind, placebo-controlled trial in subjects with genotype 1 infection, with or without cirrhosis, with chronic kidney disease (CKD) Stage 4 (eGFR 15-29 mL/min/1.73 m<sup>2</sup>) or CKD Stage 5 (eGFR &lt;15 mL/min/1.73 m<sup>2</sup>), including subjects on hemodialysis, who were treatment-naÃ¯ve or who had failed prior therapy with IFN or PegIFN Â± RBV therapy. Subjects were randomized in a 1:1 ratio to one of the following treatment groups: EBR 50 mg once daily + GZR 100 mg once daily for 12 weeks (immediate treatment group) or placebo for 12 weeks followed by open-label treatment with EBR + GZR for 12 weeks (deferred treatment group). In addition, 11 subjects received open-label EBR + GZR for 12 weeks (intensive pharmacokinetic [PK] group). Subjects randomized to the immediate treatment group and intensive PK group had a median age of 58 years (range: 31 to 76); 75% of the subjects were male; 50% were White; 45% were Black or African American; 11% were Hispanic or Latino; 57% had baseline HCV RNA levels greater than 800,000 IU/mL; 6% had cirrhosis; and 72% had non-C/C IL28B alleles (CT or TT).</paragraph>
                        <paragraph>Treatment outcomes in subjects treated with ZEPATIER for 12 weeks in the pooled immediate treatment group and intensive PK group are presented in <linkHtml href="#t15">Table 15</linkHtml>.</paragraph>
                        <table width="75%" ID="t15">
                           <caption>Table 15: C-SURFER: SVR12 in Subjects with Severe Renal Impairment including Subjects on Hemodialysis who were Treatment-NaÃ¯ve or had Failed Prior IFN or PegIFN Â± RBV, with or without Cirrhosis, with Genotype 1 HCV Treated with ZEPATIER for 12 Weeks</caption>
                           <col width="50%" align="left" valign="bottom"/>
                           <col width="50%" align="center" valign="bottom"/>
                           <thead>
                              <tr>
                                 <th styleCode="Lrule Rrule" align="center" valign="top">Regimen</th>
                                 <th styleCode="Rrule" valign="top">EBR + GZR<br/>12 weeks<br/>(Immediate Treatment Group)<br/>N=122<footnote>Includes subjects (n=11) in the intensive PK group. </footnote>
                                 </th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Overall SVR</td>
                                 <td styleCode="Rrule">94% (115/122)<footnote>SVR was achieved in 99% (115/116) of subjects in the pre-specified primary analysis population, which excluded subjects not receiving at least one dose of study treatment and those with missing data due to death or early study discontinuation for reasons unrelated to treatment response.</footnote>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" colspan="2" align="left" valign="bottom">Outcome for subjects without SVR</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">Â Â On-treatment Virologic Failure</td>
                                 <td styleCode="Rrule">0% (0/122)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">Â Â Relapse</td>
                                 <td styleCode="Rrule">&lt;1% (1/122)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â Other<footnote>Other includes subjects who discontinued due to adverse event, lost to follow-up, or subject withdrawal.</footnote>
                                 </td>
                                 <td styleCode="Rrule">5% (6/122)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" colspan="2" align="left" valign="bottom">SVR by Genotype</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">Â Â GT 1a</td>
                                 <td styleCode="Rrule">97% (61/63)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â GT 1b<footnote>Includes genotype 1 subtypes other than 1a or 1b.</footnote>
                                 </td>
                                 <td styleCode="Rrule">92% (54/59)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" colspan="2" align="left" valign="bottom">SVR by Cirrhosis status</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">Â Â No</td>
                                 <td styleCode="Rrule">95% (109/115)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â Yes</td>
                                 <td styleCode="Rrule">86% (6/7)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" colspan="2" align="left" valign="bottom">SVR by Prior HCV Treatment Status</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">Â Â Treatment-naÃ¯ve</td>
                                 <td styleCode="Rrule">95% (96/101)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â Treatment-experienced</td>
                                 <td styleCode="Rrule">90% (19/21)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" colspan="2" align="left" valign="bottom">SVR by Dialysis Status</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">Â Â No</td>
                                 <td styleCode="Rrule">97% (29/30)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â Yes</td>
                                 <td styleCode="Rrule">93% (86/92)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" colspan="2" align="left" valign="bottom">SVR by Chronic Kidney Disease Stage</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">Â Â Stage 4</td>
                                 <td styleCode="Rrule">100% (22/22)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">Â Â Stage 5</td>
                                 <td styleCode="Rrule">93% (93/100)</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20160128"/>
                  </section>
               </component>
               <component>
                  <section ID="S14.5">
                     <id root="d8d0f029-f4ce-48e8-9431-ac48f8bef1c5"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.5	Clinical Trials with Genotype 4 HCV</title>
                     <text>
                        <paragraph>The efficacy of ZEPATIER in subjects with genotype 4 chronic HCV infection was demonstrated in C-EDGE TN, C-EDGE COINFECTION, C-EDGE TE, and C-SCAPE. C-SCAPE was a randomized, open-label trial which included treatment-naÃ¯ve subjects with genotype 4 infection without cirrhosis. Subjects were randomized in a 1:1 ratio to EBR 50 mg once daily + GZR 100 mg once daily for 12 weeks or EBR 50 mg once daily + GZR 100 mg once daily + RBV for 12 weeks. In these combined studies in subjects with genotype 4 infection, 64% were treatment-naÃ¯ve; 66% of the subjects were male; 87% were White; 10% were Black or African American; 22% had cirrhosis; and 30% had HCV/HIV-1 co-infection. </paragraph>
                        <paragraph>In C-SCAPE, C-EDGE TN, and C-EDGE COINFECTION trials combined, a total of 66 genotype 4 treatment-naÃ¯ve subjects received ZEPATIER or EBR + GZR for 12 weeks. In these combined trials, SVR12 among subjects treated with ZEPATIER or EBR + GZR for 12 weeks was 97% (64/66). </paragraph>
                        <paragraph>In C-EDGE TE, a total of 37 genotype 4 treatment-experienced subjects received a 12- or 16-week ZEPATIER with or without RBV regimen. SVR12 among randomized subjects treated with ZEPATIER + RBV for 16 weeks was 100% (8/8). </paragraph>
                     </text>
                     <effectiveTime value="20160128"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S16">
               <id root="ca785d54-90b9-46aa-b92f-a99425943a27"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>Each ZEPATIER tablet contains 50 mg elbasvir and 100 mg grazoprevir, is beige, oval-shaped, film-coated, debossed with "770" on one side and plain on the other. The tablets are packaged into a carton (NDC 0006-3074-02) containing two (2) 14-count child-resistant dose packs for a total of 28 tablets.</paragraph>
               </text>
               <effectiveTime value="20160128"/>
               <component>
                  <section>
                     <id root="90dc5ae8-209a-4f1c-b719-f3a8f7c195db"/>
                     <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
                     <text>
                        <paragraph>Store ZEPATIER in the original blister package until use to protect from moisture.</paragraph>
                        <paragraph>Store ZEPATIER at 20Â°C to 25Â°C (68Â°F to 77Â°F); excursions permitted between 15Â°C to 30Â°C (between 59Â°F to 86Â°F) [see USP Controlled Room Temperature].</paragraph>
                     </text>
                     <effectiveTime value="20160128"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S17">
               <id root="d55e6d5f-473b-46eb-9f4c-5848d3926efd"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>Advise the patient to read the FDA-approved patient labeling (<linkHtml href="#PPI">Patient Information</linkHtml>). </paragraph>
                  <paragraph>For patients receiving ZEPATIER with ribavirin, advise patients to read the FDA-approved patient labeling (Medication Guide) for ribavirin <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]</content>.</paragraph>
               </text>
               <effectiveTime value="20160128"/>
               <component>
                  <section>
                     <id root="e320acd0-281b-4055-99c7-46f7574f2ad4"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk of ALT Elevations</content>
                        </paragraph>
                        <paragraph>Inform patients to watch for early warning signs of liver inflammation, such as fatigue, weakness, lack of appetite, nausea and vomiting, as well as later signs such as jaundice and discolored feces, and to consult their healthcare professional without delay if such symptoms occur <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml> and <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20160128"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="106725b4-518d-44c2-a392-6fe60db263e7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Pregnancy</content>
                        </paragraph>
                        <paragraph>Advise patients taking ZEPATIER with ribavirin to avoid pregnancy during treatment and within 6 months of stopping ribavirin and to notify their healthcare provider immediately in the event of a pregnancy <content styleCode="italics">[see <linkHtml href="#S8.1">Use in Specific Populations (8.1)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20160128"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="4e41bb0b-be52-4026-9e5f-525e67a45f82"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Drug Interactions</content>
                        </paragraph>
                        <paragraph>Inform patients that ZEPATIER may interact with some drugs; therefore, advise patients to report the use of any prescription, non-prescription medication, or herbal products to their healthcare provider <content styleCode="italics">[see <linkHtml href="#S4">Contraindications (4)</linkHtml>, <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>, and <linkHtml href="#S7">Drug Interactions (7)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20160128"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="5d3a591a-1a47-40f4-9d21-4a3cd81a6598"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Storage </content>
                        </paragraph>
                        <paragraph>Advise patients to store ZEPATIER in the original package until use to protect from moisture <content styleCode="italics">[see <linkHtml href="#S16">How Supplied/Storage and Handling (16)</linkHtml>]</content>. </paragraph>
                     </text>
                     <effectiveTime value="20160128"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="41ed94d8-f8ab-42c7-afee-eb51a1b59488"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Administration</content>
                        </paragraph>
                        <paragraph>Advise patients to take ZEPATIER every day at the regularly scheduled time with or without food. Inform patients that it is important not to miss or skip doses and to take ZEPATIER for the duration that is recommended by the healthcare provider.</paragraph>
                     </text>
                     <effectiveTime value="20160128"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="1ae53313-fb53-4969-8f39-49641519c0f5"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph>Manufactured for: Merck Sharp &amp; Dohme Corp., a subsidiary of<br/>
                     <content styleCode="bold">MERCK &amp; CO., INC.,</content> Whitehouse Station, NJ 08889, USA</paragraph>
                  <paragraph>Manufactured by:<br/>MSD International GmbH, Ballydine, Clonmel, Ireland</paragraph>
                  <paragraph>For patent information: www.merck.com/product/patent/home.html</paragraph>
                  <paragraph>Copyright Â© 2016 Merck Sharp &amp; Dohme Corp., a subsidiary of <content styleCode="bold">Merck &amp; Co., Inc.</content>
                     <br/>All rights reserved.</paragraph>
                  <paragraph>uspi-mk5172a-t-1601r000</paragraph>
               </text>
               <effectiveTime value="20160128"/>
            </section>
         </component>
         <component>
            <section ID="PPI">
               <id root="629c2317-132c-45bd-a7b6-ae606f4d42d9"/>
               <code code="42230-3" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PATIENT PACKAGE INSERT SECTION"/>
               <text>
                  <table width="100%" styleCode="Noautorules">
                     <col width="100%" align="center" valign="middle"/>
                     <tbody>
                        <tr>
                           <td styleCode="Rrule Lrule Toprule Botrule">
                              <content styleCode="bold">Patient Information<br/>ZEPATIERâ„¢ (ZEP-ah-teer)</content>
                              <br/>(elbasvir and grazoprevir)<br/>tablets</td>
                        </tr>
                     </tbody>
                  </table>
                  <table width="100%" styleCode="Noautorules">
                     <col width="100%" align="left" valign="middle"/>
                     <tbody>
                        <tr>
                           <td styleCode="Rrule Lrule Toprule Botrule">
                              <content styleCode="bold">What you need to know about ZEPATIER</content>
                              <list listType="unordered">
                                 <item>Before you take this medicine, be sure you understand what it is for and how to take it safely.</item>
                                 <item>Keep this information. </item>
                                 <item>If you have questions about this medicine, ask your healthcare provider or pharmacist.</item>
                                 <item>Every time you get a refill, look at the Patient Information. There may be new information.</item>
                                 <item>Your healthcare provider may prescribe ZEPATIER with a medicine called ribavirin. Ribavirin is also known as Rebetol<sup>Â®</sup>, Copegus<sup>Â®</sup>, Ribasphere<sup>Â®</sup>, and Moderiba<sup>Â®</sup>. <content styleCode="bold">If you take ZEPATIER and ribavirin, be sure you read the Medication Guide for ribavirin.</content>
                                 </item>
                              </list>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <table width="100%" styleCode="Noautorules">
                     <col width="100%" align="left" valign="top"/>
                     <tbody>
                        <tr>
                           <td styleCode="Botrule">
                              <content styleCode="bold">What is ZEPATIERâ„¢?</content>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>ZEPATIER is a prescription medicine used with or without ribavirin to treat chronic (long-lasting) hepatitis C virus (HCV) genotypes 1 or 4 infection in adults.</paragraph>
                  <paragraph>It is not known if ZEPATIER is safe or effective in children under 18 years old, people awaiting a liver transplant, or people who have had a liver transplant.</paragraph>
                  <table width="100%" styleCode="Noautorules">
                     <col width="100%" align="left" valign="top"/>
                     <tbody>
                        <tr>
                           <td styleCode="Botrule">
                              <content styleCode="bold" ID="should_not">Who should not take ZEPATIER? </content>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>Do not take ZEPATIER if you have certain liver problems.</paragraph>
                  <table width="100%" styleCode="Noautorules">
                     <col width="100%" align="left" valign="top"/>
                     <tbody>
                        <tr>
                           <td styleCode="Botrule">
                              <content styleCode="bold">What should I tell my healthcare provider before taking ZEPATIER?</content>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>Tell your healthcare provider if you: </paragraph>
                  <list listType="unordered">
                     <item>have liver problems other than hepatitis C</item>
                     <item>have ever taken any medicine for hepatitis C </item>
                     <item>have HIV</item>
                     <item>have had or are waiting for a liver transplant</item>
                     <item>have any other medical conditions</item>
                     <item>are pregnant or trying to get pregnant. ZEPATIER has not been studied in pregnant women. We do not know if ZEPATIER will harm your baby while you are pregnant. 							<list listType="unordered" styleCode="circle">
                           <item>
                              <content styleCode="bold">Males and females who take ZEPATIER and ribavirin should also read the ribavirin Medication Guide for important pregnancy, contraception, and infertility information. </content>
                           </item>
                        </list>
                     </item>
                     <item>are breastfeeding or plan to breastfeed. We do not know if ZEPATIER gets in your breast milk and gets passed to your baby. 							<list listType="unordered" styleCode="circle">
                           <item>
                              <content styleCode="bold">Talk to your healthcare provider about the best way to feed your baby during treatment with ZEPATIER. </content>
                           </item>
                        </list>
                     </item>
                  </list>
                  <table width="100%" styleCode="Noautorules">
                     <col width="100%" align="left" valign="top"/>
                     <tbody>
                        <tr>
                           <td styleCode="Botrule">
                              <content styleCode="bold">Are you taking other medicines?</content>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">Tell your healthcare provider about all of the medicines you take</content>, including prescription and over-the-counter medicines, vitamins, and herbal supplements. ZEPATIER may affect the way other medicines work, and other medicines may affect how ZEPATIER works. Some medicines cannot be taken with ZEPATIER. Your healthcare provider can tell you if it is safe to take ZEPATIER with other medicines.</paragraph>
                  <list listType="unordered">
                     <item>Know the medicines you take. Keep a list of your medicines and show it to your healthcare provider and pharmacist when you get a new medicine.</item>
                     <item>You can ask your healthcare provider or pharmacist for a list of medicines that interact with this medicine.</item>
                     <item>
                        <content styleCode="bold">Do not start taking a new medicine without telling your healthcare provider.</content>
                     </item>
                  </list>
                  <table width="100%" styleCode="Noautorules">
                     <col width="100%" align="left" valign="top"/>
                     <tbody>
                        <tr>
                           <td styleCode="Botrule">
                              <content styleCode="bold">How do I take ZEPATIER?</content>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <list listType="unordered">
                     <item>
                        <content styleCode="bold">Take 1 ZEPATIER tablet at the same time every day.</content>
                     </item>
                     <item>ZEPATIER comes in a blister package of individually-packaged tablets. Keep the tablets in this package until you are ready to take your dose.</item>
                     <item>Take ZEPATIER exactly as your healthcare provider tells you to take it.</item>
                     <item>Take ZEPATIER with or without food. </item>
                     <item>Do not stop taking ZEPATIER without first talking with your healthcare provider. </item>
                     <item>If you take more than your prescribed dose, call your healthcare provider right away.</item>
                  </list>
                  <table width="100%" styleCode="Noautorules">
                     <col width="100%" align="left" valign="top"/>
                     <tbody>
                        <tr>
                           <td styleCode="Botrule">
                              <content styleCode="bold">What if I forget to take ZEPATIER?</content>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <list listType="unordered">
                     <item>Do not take two doses of ZEPATIER at the same time to make up for a missed dose. </item>
                     <item>If you are not sure what to do, call your healthcare provider or pharmacist. It is important that you do not miss or skip doses of ZEPATIER during treatment.</item>
                  </list>
                  <table width="100%" styleCode="Noautorules">
                     <col width="100%" align="left" valign="top"/>
                     <tbody>
                        <tr>
                           <td styleCode="Botrule">
                              <content styleCode="bold">What are the possible side effects of ZEPATIER?</content>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">Signs of liver problems. ZEPATIER may cause increases in your liver-related blood tests</content>. This could be a sign of serious liver problems. Your healthcare provider will do blood tests to check your liver before and during treatment with ZEPATIER. Tell your healthcare provider right away if you get any of the following symptoms or if they get worse during treatment with ZEPATIER:</paragraph>
                  <table width="75%" styleCode="Noautorules">
                     <col width="55%" align="left" valign="top"/>
                     <col width="45%" align="left" valign="top"/>
                     <tbody>
                        <tr>
                           <td>
                              <list listType="unordered" styleCode="Disc">
                                 <item>loss of appetite</item>
                                 <item>nausea and vomiting</item>
                                 <item>feeling tired or weak</item>
                              </list>
                           </td>
                           <td>
                              <list listType="unordered" styleCode="Disc">
                                 <item>yellowing of your skin or eyes</item>
                                 <item>color changes in your stool</item>
                              </list>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">Common side effects of ZEPATIER when used without ribavirin include:</content>
                  </paragraph>
                  <table width="75%" styleCode="Noautorules">
                     <col width="55%" align="left" valign="top"/>
                     <col width="45%" align="left" valign="top"/>
                     <tbody>
                        <tr>
                           <td>
                              <list listType="unordered" styleCode="Disc">
                                 <item>feeling tired</item>
                                 <item>headache</item>
                                 <item>nausea</item>
                              </list>
                           </td>
                           <td>
                              <list listType="unordered" styleCode="Disc">
                                 <item>trouble sleeping</item>
                                 <item>diarrhea</item>
                              </list>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">Common side effects of ZEPATIER when used with ribavirin include:</content>
                  </paragraph>
                  <table width="75%" styleCode="Noautorules">
                     <col width="55%" align="left" valign="top"/>
                     <col width="45%" align="left" valign="top"/>
                     <tbody>
                        <tr>
                           <td>
                              <list listType="unordered" styleCode="Disc">
                                 <item>low red blood cell counts (anemia)</item>
                                 <item>headache</item>
                                 <item>feeling tired</item>
                                 <item>shortness of breath</item>
                                 <item>rash or itching</item>
                              </list>
                           </td>
                           <td>
                              <list listType="unordered" styleCode="Disc">
                                 <item>feeling irritable</item>
                                 <item>stomach pain</item>
                                 <item>depression</item>
                                 <item>joint pain</item>
                              </list>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">If you have any side effect that bothers you or that does not go away, tell your healthcare provider.</content>
                  </paragraph>
                  <paragraph>There may be other side effects to ZEPATIER that are not listed. </paragraph>
                  <paragraph>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. For more information or medical advice call your doctor.</paragraph>
                  <table width="100%" styleCode="Noautorules">
                     <col width="100%" align="left" valign="top"/>
                     <tbody>
                        <tr>
                           <td styleCode="Botrule">
                              <content styleCode="bold">Where should I keep ZEPATIER?</content>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <list listType="unordered">
                     <item>Keep ZEPATIER in its original packaging (blister package) until you are ready to take it. Do not take the tablets out of the original blister package to store in another container such as a pill box. This is important because the tablets are sensitive to moisture. The package is designed to protect them.</item>
                     <item>Keep ZEPATIER at room temperature.</item>
                     <item>Keep ZEPATIER and all medicines out of the reach of children.</item>
                  </list>
                  <table width="100%" styleCode="Noautorules">
                     <col width="100%" align="left" valign="top"/>
                     <tbody>
                        <tr>
                           <td styleCode="Botrule">
                              <content styleCode="bold">General information about ZEPATIER</content>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <list listType="unordered">
                     <item>Medicines are sometimes prescribed for purposes other than those listed in the patient information. Do not use ZEPATIER for a condition for which it was not prescribed. Do not give ZEPATIER to other people, even if they have the same condition. It may harm them.</item>
                     <item>If you would like more information, talk with your healthcare provider or pharmacist. You can ask them for information about ZEPATIER that was written for health professionals.</item>
                     <item>For more information, call Merck, the company that makes ZEPATIER, at 1-877-888-4231 or go to www.ZEPATIER.com.</item>
                  </list>
                  <table width="100%" styleCode="Noautorules">
                     <col width="100%" align="left" valign="top"/>
                     <tbody>
                        <tr>
                           <td styleCode="Botrule">
                              <content styleCode="bold">What are the ingredients in ZEPATIER?</content>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>The active ingredients are: elbasvir and grazoprevir.</paragraph>
                  <paragraph>The inactive ingredients are: colloidal silicon dioxide, copovidone, croscarmellose sodium, hypromellose, lactose monohydrate, magnesium stearate, mannitol, microcrystalline cellulose, sodium chloride, sodium lauryl sulfate, and vitamin E polyethylene glycol succinate. </paragraph>
                  <paragraph>The tablets are film-coated with a coating material containing the following inactive ingredients: carnauba wax, ferrosoferric oxide, hypromellose, iron oxide red, iron oxide yellow, lactose monohydrate, titanium dioxide, and triacetin.</paragraph>
                  <table width="100%" styleCode="Noautorules">
                     <col width="100%" align="left" valign="top"/>
                     <tbody>
                        <tr>
                           <td styleCode="Botrule">Â </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>This Patient Information has been approved by the U.S. Food and Drug Administration.</paragraph>
               </text>
               <effectiveTime value="20160128"/>
            </section>
         </component>
         <component>
            <section>
               <id root="bb3b8b68-dfc5-4dee-8ccd-f6d54df68808"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph>Manufactured for: Merck Sharp &amp; Dohme Corp., a subsidiary of<br/>
                     <content styleCode="bold">MERCK &amp; CO., INC.,</content> Whitehouse Station, NJ 08889, USA</paragraph>
                  <paragraph>Manufactured by:<br/>MSD International GmbH, Ballydine, Clonmel, Ireland<br/>For patent information: www.merck.com/product/patent/home.html<br/>The trademarks depicted herein are owned by their respective companies.<br/>Copyright Â© 2016 Merck Sharp &amp; Dohme Corp., a subsidiary of <content styleCode="bold">Merck &amp; Co., Inc.</content>
                     <br/>All rights reserved.</paragraph>
                  <paragraph>Issued: 1/2016<br/>usppi-mk5172a-t-1601r000</paragraph>
               </text>
               <effectiveTime value="20160128"/>
            </section>
         </component>
         <component>
            <section>
               <id root="fecd6ee7-f64d-47bd-8d04-1cd42d686c7f"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 28 Tablet Dose Pack Carton</title>
               <text>
                  <paragraph>NDC 0006-3074-02</paragraph>
                  <paragraph>
                     <content styleCode="bold">Zepatierâ„¢<br/>(elbasvir and grazoprevir) tablets</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">50 mg/100 mg</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
                  <paragraph>28 Tablets</paragraph>
                  <paragraph>This carton contains a total of 28 tablets<br/>packaged within 2 dose packs.<br/>Each dose pack contains 14 blister units<br/>with one tablet per blister unit.</paragraph>
                  <renderMultiMedia referencedObject="MM3"/>
               </text>
               <effectiveTime value="20160128"/>
               <component>
                  <observationMedia ID="MM3">
                     <text>PRINCIPAL DISPLAY PANEL - 28 Tablet Dose Pack Carton</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="zepatier-03.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>